

Reversion of advanced Ebola virus disease in nonhuman

Nature

514, 47-53

DOI: [10.1038/nature13777](https://doi.org/10.1038/nature13777)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Ebola Viral Disease Outbreak-2014: Implications and Pitfalls. <i>Frontiers in Public Health</i> , 2014, 2, 263.	2.7	7
2	Plant-based solutions for veterinary immunotherapeutics and prophylactics. <i>Veterinary Research</i> , 2014, 45, 117.	3.0	50
3	Plant-based vaccines against viruses. <i>Virology Journal</i> , 2014, 11, 205.	3.4	126
4	Transmission dynamics and control of Ebola virus disease (EVD): a review. <i>BMC Medicine</i> , 2014, 12, 196.	5.5	300
5	Ebola virus disease: where are we now and where do we go?. <i>Postgraduate Medical Journal</i> , 2014, 90, 610-612.	1.8	8
6	Human Ebola virus infection in West Africa: a review of available therapeutic agents that target different steps of the life cycle of Ebola virus. <i>Infectious Diseases of Poverty</i> , 2014, 3, 43.	3.7	23
7	The quest for effective Ebola treatment: Ebola VP35 is an evidence-based target for dsRNA drugs. <i>Emerging Microbes and Infections</i> , 2014, 3, 1-2.	6.5	7
8	Identification of 53 compounds that block Ebola virus-like particle entry via a repurposing screen of approved drugs. <i>Emerging Microbes and Infections</i> , 2014, 3, 1-7.	6.5	200
9	Euthanasia Assessment in Ebola Virus Infected Nonhuman Primates. <i>Viruses</i> , 2014, 6, 4666-4682.	3.3	22
10	Ebola virus disease. <i>BMJ, The</i> , 2014, 349, g7348-g7348.	6.0	139
11	Ebola virus: Questions, answers, and more questions. <i>Cleveland Clinic Journal of Medicine</i> , 2014, 81, 729-735.	1.3	4
12	The Ebola Virus Matrix Protein VP40 Selectively Induces Vesiculation from Phosphatidylserine-enriched Membranes. <i>Journal of Biological Chemistry</i> , 2014, 289, 33590-33597.	3.4	54
13	Extracorporeal Virus Elimination for the Treatment of Severe Ebola Virus Disease - First Experience with Lectin Affinity Plasmapheresis. <i>Blood Purification</i> , 2014, 38, 286-291.	1.8	38
14	Evaluating Novel Therapies During the Ebola Epidemic. <i>JAMA - Journal of the American Medical Association</i> , 2014, 312, 1299.	7.4	63
15	Ebola: a review on the state of the art on prevention and treatment. <i>Asian Pacific Journal of Tropical Biomedicine</i> , 2014, 4, 925-927.	1.2	4
16	The Ebola virus: a review of progress and development in research. <i>Asian Pacific Journal of Tropical Biomedicine</i> , 2014, 4, 928-936.	1.2	9
17	Ebolavirus in West Africa, and the use of experimental therapies or vaccines. <i>BMC Biology</i> , 2014, 12, 80.	3.8	20
18	Ebola virus infection: What should be known?. <i>North American Journal of Medical Sciences</i> , 2014, 6, 549.	1.7	24

#	ARTICLE	IF	CITATIONS
19	A Dead-End Host: Is There a Way Out? A Position Piece on the Ebola Virus Outbreak by the International Union of Immunology Societies. <i>Frontiers in Immunology</i> , 2014, 5, 562.	4.8	1
20	Drug development for controlling Ebola epidemic – A race against time. <i>Drug Discoveries and Therapeutics</i> , 2014, 8, 229-231.	1.5	16
21	Ebola Conquers West Africa – More to Come?. <i>EBioMedicine</i> , 2014, 1, 2-3.	6.1	1
22	Structures of protective antibodies reveal sites of vulnerability on Ebola virus. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 17182-17187.	7.1	173
24	Clinical Care of Two Patients with Ebola Virus Disease in the United States. <i>New England Journal of Medicine</i> , 2014, 371, 2402-2409.	27.0	310
25	Ebola Hemorrhagic Fever: Genetic Biomarkers and Vaccine Development. <i>Genetic Testing and Molecular Biomarkers</i> , 2014, 18, 715-716.	0.7	2
26	Biopharmaceutical benchmarks 2014. <i>Nature Biotechnology</i> , 2014, 32, 992-1000.	17.5	825
27	Ebola therapy protects severely ill monkeys. <i>Nature</i> , 2014, 514, 41-43.	27.8	14
28	US signs contract with ZMapp maker to accelerate development of the Ebola drug. <i>BMJ</i> , The, 2014, 349, g5488-g5488.	6.0	67
29	Ebola update. <i>Nature Reviews Microbiology</i> , 2014, 12, 656-656.	28.6	1
30	Clinical features and pathobiology of Ebolavirus infection. <i>Journal of Autoimmunity</i> , 2014, 55, 1-9.	6.5	123
31	Priorities for Ebola virus disease response in west Africa. <i>Lancet</i> , The, 2014, 384, 1843.	13.7	20
32	New Hope in the Search for Ebola Virus Treatments. <i>Immunity</i> , 2014, 41, 515-517.	14.3	2
33	The Ebola questions. <i>Nature</i> , 2014, 514, 554-557.	27.8	13
34	Ebola Virus Potential Drug Targets and Prospects for Small Molecule Drug Discovery. <i>Journal of Pharmaceutical Sciences and Pharmacology</i> , 2014, 1, 313-321.	0.2	1
35	Plant-produced candidate countermeasures against emerging and reemerging infections and bioterror agents. <i>Plant Biotechnology Journal</i> , 2015, 13, 1136-1159.	8.3	37
36	Commercial-scale biotherapeutics manufacturing facility for plant-made pharmaceuticals. <i>Plant Biotechnology Journal</i> , 2015, 13, 1180-1190.	8.3	148
37	Regulatory approval and a first-in-human phase I clinical trial of a monoclonal antibody produced in transgenic tobacco plants. <i>Plant Biotechnology Journal</i> , 2015, 13, 1106-1120.	8.3	205

#	ARTICLE	IF	CITATIONS
38	Fc receptors in antibody-dependent enhancement of viral infections. <i>Immunological Reviews</i> , 2015, 268, 340-364.	6.0	202
39	Ebola virus disease: societal challenges and new treatments. <i>Journal of Internal Medicine</i> , 2015, 278, 227-237.	6.0	6
40	Clinical Management of Ebola Virus Disease: Current and Future Approaches. <i>Topics in Medicinal Chemistry</i> , 2015, , 1-36.	0.8	0
41	Facile Discovery of a Diverse Panel of Anti-Ebola Virus Antibodies by Immune Repertoire Mining. <i>Scientific Reports</i> , 2015, 5, 13926.	3.3	47
42	The emergence of antibody therapies for Ebola. <i>Human Antibodies</i> , 2015, 23, 49-56.	1.5	37
43	RTB Lectin: a novel receptor-independent delivery system for lysosomal enzyme replacement therapies. <i>Scientific Reports</i> , 2015, 5, 14144.	3.3	27
44	Working on the front line. <i>Clinical Medicine</i> , 2015, 15, 358-361.	1.9	4
45	é†ç—†ã,“ãfœãf ©ã, ã,ãf«ã,¹æ,,ÿæÿ“ç—†ã®ã,µãf«ã,â»žã¼ ©ã•ã»ãÿæ²»ç™,è—ã. <i>Nature Digest</i> , 2015, 12, 26-27.	0.0	0
46	Ebolavirus Vaccines: Progress in the Fight Against Ebola Virus Disease. <i>Cellular Physiology and Biochemistry</i> , 2015, 37, 1641-1658.	1.6	8
47	Ebola: an analysis of immunity at the molecular level. , 2015, , .		1
48	Development of Small-Molecule Antivirals for Ebola. <i>Medicinal Research Reviews</i> , 2015, 35, 1175-1194.	10.5	10
49	Ebola in Children. <i>Pediatric Infectious Disease Journal</i> , 2015, 34, 314-316.	2.0	17
50	Leishmania tarentolae: an alternative approach to the production of monoclonal antibodies to treat emerging viral infections. <i>Infectious Diseases of Poverty</i> , 2015, 4, 8.	3.7	11
51	Within leaf variation is the largest source of variation in agroinfiltration of <i>Nicotiana benthamiana</i> . <i>Plant Methods</i> , 2015, 11, 47.	4.3	42
52	Artifact-Free Quantification and Sequencing of Rare Recombinant Viruses by Using Drop-Based Microfluidics. <i>ChemBioChem</i> , 2015, 16, 2167-2171.	2.6	28
53	Ebola virus outbreak, updates on current therapeutic strategies. <i>Reviews in Medical Virology</i> , 2015, 25, 241-253.	8.3	9
54	China takes an active role in combating an Ebola outbreak: On-site observations and reflections from a Chinese healthcare provider. <i>Intractable and Rare Diseases Research</i> , 2015, 4, 217-219.	0.9	7
56	Toward a two-tier process-development paradigm: prototype versus commercial biomanufacturing. <i>Pharmaceutical Bioprocessing</i> , 2015, 3, 179-183.	0.8	1

#	ARTICLE	IF	CITATIONS
57	31st annual meeting of the Pan American Society for Clinical Virology and Clinical Virology Symposium, Daytona Beach, FL, USA, 26-29 April 2015. <i>Future Virology</i> , 2015, 10, 1129-1132.	1.8	0
58	The use of convalescent plasma to treat emerging infectious diseases. <i>Current Opinion in Hematology</i> , 2015, 22, 521-526.	2.5	43
59	Ebola Virus Disease. <i>Anesthesia and Analgesia</i> , 2015, 121, 798-809.	2.2	43
60	Prospects for engineering HIV-specific antibodies for enhanced effector function and half-life. <i>Current Opinion in HIV and AIDS</i> , 2015, 10, 160-169.	3.8	21
61	Critical Care for Multiple Organ Failure Secondary to Ebola Virus Disease in the United States*. <i>Critical Care Medicine</i> , 2015, 43, 2066-2075.	0.9	30
62	Ebola Virus Disease. <i>Pediatric Infectious Disease Journal</i> , 2015, 34, 893-897.	2.0	28
63	Ebola Virus Disease: From Disaster to Containment. <i>Bangladesh Journal of Medicine</i> , 2015, 26, 1-3.	0.1	1
64	Progress of vaccine and drug development for Ebola preparedness. <i>Clinical and Experimental Vaccine Research</i> , 2015, 4, 11.	2.2	29
65	An Overview of Ebola Virus Disease: History, Pathogenesis, and Treatment. <i>Juntendo Medical Journal</i> , 2015, 61, 396-406.	0.1	1
66	Filoviruses: One of These Things is (not) Like the Other. <i>Viruses</i> , 2015, 7, 5172-5190.	3.3	27
67	Ebola Virus Infections in Nonhuman Primates Are Temporally Influenced by Glycoprotein Poly-U Editing Site Populations in the Exposure Material. <i>Viruses</i> , 2015, 7, 6739-6754.	3.3	29
68	Plants as Factories for Human Pharmaceuticals: Applications and Challenges. <i>International Journal of Molecular Sciences</i> , 2015, 16, 28549-28565.	4.1	203
69	Use of Viremia to Evaluate the Baseline Case Fatality Ratio of Ebola Virus Disease and Inform Treatment Studies: A Retrospective Cohort Study. <i>PLoS Medicine</i> , 2015, 12, e1001908.	8.4	54
70	Antiviral Biologic Produced in DNA Vaccine/Goose Platform Protects Hamsters Against Hantavirus Pulmonary Syndrome When Administered Post-exposure. <i>PLoS Neglected Tropical Diseases</i> , 2015, 9, e0003803.	3.0	39
71	Protective mAbs and Cross-Reactive mAbs Raised by Immunization with Engineered Marburg Virus GPs. <i>PLoS Pathogens</i> , 2015, 11, e1005016.	4.7	36
72	Monitoring of Ebola Virus Makona Evolution through Establishment of Advanced Genomic Capability in Liberia. <i>Emerging Infectious Diseases</i> , 2015, 21, 1135-1143.	4.3	79
73	Production of Monoclonal Antibodies in Plants for Cancer Immunotherapy. <i>BioMed Research International</i> , 2015, 2015, 1-9.	1.9	27
74	Ebola Virus: The need to take some preventive measures. <i>Pakistan Journal of Medical Sciences</i> , 2015, 31, 483-6.	0.6	1

#	ARTICLE	IF	CITATIONS
75	Evaluating Large-scale Blood Transfusion Therapy for the Current Ebola Epidemic in Liberia. <i>Journal of Infectious Diseases</i> , 2015, 211, 1262-1267.	4.0	19
76	Care of the Child With Ebola Virus Disease*. <i>Pediatric Critical Care Medicine</i> , 2015, 16, 97-103.	0.5	20
77	Gastrointestinal and Hepatic Manifestations of Ebola Virus Infection. <i>Digestive Diseases and Sciences</i> , 2015, 60, 2590-2603.	2.3	16
78	Characterization of a Bivalent Vaccine Capable of Inducing Protection Against Both Ebola and Cross-clade H5N1 Influenza in Mice. <i>Journal of Infectious Diseases</i> , 2015, 212, S435-S442.	4.0	9
79	The crux and crust of ebolavirus: Analysis of genome sequences and glycoprotein gene. <i>Biochemical and Biophysical Research Communications</i> , 2015, 463, 756-761.	2.1	3
80	Evaluation of the Potential Impact of Ebola Virus Genomic Drift on the Efficacy of Sequence-Based Candidate Therapeutics. <i>MBio</i> , 2015, 6, .	4.1	62
81	Bioethical Challenges of the Ebola Outbreak. <i>Journal of Bioethical Inquiry</i> , 2015, 12, 173-175.	1.5	1
82	Mechanism of Human Antibody-Mediated Neutralization of Marburg Virus. <i>Cell</i> , 2015, 160, 893-903.	28.9	130
83	Structural Basis for Marburg Virus Neutralization by a Cross-Reactive Human Antibody. <i>Cell</i> , 2015, 160, 904-912.	28.9	110
84	Mission Critical. <i>Veterinary Pathology</i> , 2015, 52, 18-20.	1.7	4
85	The Ebola epidemic is ongoing in West Africa and responses from China are positive. <i>Military Medical Research</i> , 2015, 2, 9.	3.4	6
86	Are adaptive randomised trials or non-randomised studies the best way to address the Ebola outbreak in west Africa?. <i>Lancet Infectious Diseases</i> , The, 2015, 15, 738-745.	9.1	42
87	Treatment of Ebola virus infections with inhibitors of TLR4. <i>Medical Hypotheses</i> , 2015, 85, 253-257.	1.5	4
88	Emergency Postexposure Vaccination With Vesicular Stomatitis Virus-Vectored Ebola Vaccine After Needlestick. <i>JAMA - Journal of the American Medical Association</i> , 2015, 313, 1249.	7.4	82
89	The multifunctional Ebola virus VP40 matrix protein is a promising therapeutic target. <i>Future Virology</i> , 2015, 10, 537-546.	1.8	51
90	Gene Therapy for Infection with Hemorrhagic Fever Viruses. , 2015, , 299-316.		0
91	Co-€volution of the <sc>MHC</sc> class I and <sc>KIR</sc> gene families in rhesus macaques: ancestry and plasticity. <i>Immunological Reviews</i> , 2015, 267, 228-245.	6.0	35
92	Addressing Therapeutic Options for Ebola Virus Infection in Current and Future Outbreaks. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 5892-5902.	3.2	36

#	ARTICLE	IF	CITATIONS
93	Current and emerging strategies for the diagnosis, prevention and treatment of Lassa fever. <i>Future Virology</i> , 2015, 10, 559-584.	1.8	18
94	Ebola in the United States. <i>Journal of Allergy and Clinical Immunology</i> , 2015, 135, 868-871.	2.9	3
95	Measuring affinity constants of 1450 monoclonal antibodies to peptide targets with a microarray-based label-free assay platform. <i>Journal of Immunological Methods</i> , 2015, 417, 86-96.	1.4	113
96	Modelling the effect of early detection of Ebola. <i>Lancet Infectious Diseases</i> , The, 2015, 15, 148-149.	9.1	46
97	Flavonoids as multi-target inhibitors for proteins associated with Ebola virus: in-silico discovery using virtual screening and molecular docking studies. <i>Interdisciplinary Sciences, Computational Life Sciences</i> , 2015, , .	3.6	2
98	Development of human neutralizing monoclonal antibodies for prevention and therapy of MERS-CoV infections. <i>Microbes and Infection</i> , 2015, 17, 142-148.	1.9	30
99	Expression of H3N2 nucleoprotein in maize seeds and immunogenicity in mice. <i>Plant Cell Reports</i> , 2015, 34, 969-980.	5.6	36
100	Treatment of Ebola Virus Disease. <i>Pharmacotherapy</i> , 2015, 35, 43-53.	2.6	50
101	Ebola: history, treatment, and lessons from a new emerging pathogen. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2015, 308, L307-L313.	2.9	4
102	Host immunity to <i>Bacillus anthracis</i> lethal factor and other immunogens: implications for vaccine design. <i>Expert Review of Vaccines</i> , 2015, 14, 429-434.	4.4	11
103	The increasing value of plant-made proteins. <i>Current Opinion in Biotechnology</i> , 2015, 32, 163-170.	6.6	120
104	Delineating Ebola entry. <i>Science</i> , 2015, 347, 947-948.	12.6	11
105	Ebola: translational science considerations. <i>Journal of Translational Medicine</i> , 2015, 13, 11.	4.4	50
106	Post-exposure treatment of Ebola virus using passive immunotherapy: proposal for a new strategy. <i>Journal of Venomous Animals and Toxins Including Tropical Diseases</i> , 2015, 21, 3.	1.4	9
107	Human Ebola virus infection results in substantial immune activation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 4719-4724.	7.1	274
109	Ebola virus disease: an update for anesthesiologists and intensivists. <i>Canadian Journal of Anaesthesia</i> , 2015, 62, 80-91.	1.6	33
110	Ebola Virus Disease: A Perspective for the United States. <i>American Journal of Medicine</i> , 2015, 128, 682-691.	1.5	10
111	Ebola virus disease: What clinicians in the United States need to know. <i>American Journal of Infection Control</i> , 2015, 43, 788-793.	2.3	15

#	ARTICLE	IF	CITATIONS
112	Molecular Characterization of the First Ebola Virus Isolated in Italy, from a Health Care Worker Repatriated from Sierra Leone. <i>Genome Announcements</i> , 2015, 3, .	0.8	10
113	Inhibition of Ebola virus glycoprotein-mediated cytotoxicity by targeting its transmembrane domain and cholesterol. <i>Nature Communications</i> , 2015, 6, 7688.	12.8	40
114	Modeling the Disease Course of <i>Zaire ebolavirus</i> Infection in the Outbred Guinea Pig. <i>Journal of Infectious Diseases</i> , 2015, 212, S305-S315.	4.0	43
115	Pre-symptomatic diagnosis and treatment of filovirus diseases. <i>Frontiers in Microbiology</i> , 2015, 6, 108.	3.5	15
116	Editorial Commentary: All's (Almost) Quiet on the Western Front: Will We Be Ready for the Next War?. <i>Clinical Infectious Diseases</i> , 2015, 61, 503-505.	5.8	1
117	Basigin is a druggable target for host-oriented antimalarial interventions. <i>Journal of Experimental Medicine</i> , 2015, 212, 1145-1151.	8.5	62
118	A Dual-Intein Autoprocessing Domain that Directs Synchronized Protein Co-Expression in Both Prokaryotes and Eukaryotes. <i>Scientific Reports</i> , 2015, 5, 8541.	3.3	18
119	Using glyco-engineering to produce therapeutic proteins. <i>Expert Opinion on Biological Therapy</i> , 2015, 15, 1501-1516.	3.1	64
120	Ebola virus disease in nonendemic countries. <i>Journal of the Formosan Medical Association</i> , 2015, 114, 384-398.	1.7	7
121	Against the clock towards new Ebola virus therapies. <i>Virus Research</i> , 2015, 209, 4-10.	2.2	14
122	Considerations in the Use of Nonhuman Primate Models of Ebola Virus and Marburg Virus Infection: Table 1.. <i>Journal of Infectious Diseases</i> , 2015, 212, S91-S97.	4.0	116
123	Human antibody technology and the development of antibodies against cytomegalovirus. <i>Molecular Immunology</i> , 2015, 67, 153-170.	2.2	20
124	Ébola: aprendizajes y perspectivas. <i>FMC Formacion Medica Continuada En Atencion Primaria</i> , 2015, 22, 59-61.	0.0	0
125	Plant-based production of two chimeric monoclonal IgG antibodies directed against immunodominant epitopes of <i>Vibrio cholerae</i> lipopolysaccharide. <i>Journal of Immunological Methods</i> , 2015, 422, 111-117.	1.4	9
126	Pathophysiology of Ebola Virus Infection: Current Challenges and Future Hopes. <i>ACS Infectious Diseases</i> , 2015, 1, 186-197.	3.8	18
127	Lipid nanoparticle siRNA treatment of Ebola-virus-Makona-infected nonhuman primates. <i>Nature</i> , 2015, 521, 362-365.	27.8	226
128	Role of EXT1 and Glycosaminoglycans in the Early Stage of Filovirus Entry. <i>Journal of Virology</i> , 2015, 89, 5441-5449.	3.4	54
129	Ebola virus disease: from epidemiology to prophylaxis. <i>Military Medical Research</i> , 2015, 2, 7.	3.4	22

#	ARTICLE	IF	CITATIONS
130	Backs against the Wall: Novel and Existing Strategies Used during the 2014-2015 Ebola Virus Outbreak. <i>Clinical Microbiology Reviews</i> , 2015, 28, 593-601.	13.6	42
131	State-of-the-Art Workshops on Medical Countermeasures Potentially Available for Human Use Following Accidental Exposures to Ebola Virus. <i>Journal of Infectious Diseases</i> , 2015, 212, S84-S90.	4.0	12
132	Therapeutics for postexposure treatment of Ebola virus infection. <i>Future Virology</i> , 2015, 10, 221-232.	1.8	5
133	Nanozyme-strip for rapid local diagnosis of Ebola. <i>Biosensors and Bioelectronics</i> , 2015, 74, 134-141.	10.1	320
134	Emergency Treatment for Exposure to Ebola Virus. <i>JAMA - Journal of the American Medical Association</i> , 2015, 313, 1221.	7.4	8
135	Adenovirus-Vectored Vaccine Provides Postexposure Protection to Ebola Virus-Infected Nonhuman Primates. <i>Journal of Infectious Diseases</i> , 2015, 212, S379-S383.	4.0	18
136	Robust and sustained immune activation in human Ebola virus infection. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 4518-4519.	7.1	5
137	The Engineered Chloroplast Genome Just Got Smarter. <i>Trends in Plant Science</i> , 2015, 20, 622-640.	8.8	142
138	A humanized neutralizing antibody against MERS-CoV targeting the receptor-binding domain of the spike protein. <i>Cell Research</i> , 2015, 25, 1237-1249.	12.0	137
139	Glycan modulation and sulfoengineering of anti-HIV-1 monoclonal antibody PG9 in plants. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 12675-12680.	7.1	44
140	Clinical Management of Ebola Virus Disease Patients. <i>Current Treatment Options in Infectious Diseases</i> , 2015, 7, 248-260.	1.9	1
141	Mechanism of Binding to Ebola Virus Glycoprotein by the ZMapp, ZMAb, and MB-003 Cocktail Antibodies. <i>Journal of Virology</i> , 2015, 89, 10982-10992.	3.4	120
142	Ebola Virus Entry into Host Cells: Identifying Therapeutic Strategies. <i>Current Clinical Microbiology Reports</i> , 2015, 2, 115-124.	3.4	34
143	Clinical features and viral kinetics in a rapidly cured patient with Ebola virus disease: a case report. <i>Lancet Infectious Diseases</i> , The, 2015, 15, 1034-1040.	9.1	46
144	Inhibition of Ebola and Marburg Virus Entry by G Protein-Coupled Receptor Antagonists. <i>Journal of Virology</i> , 2015, 89, 9932-9938.	3.4	90
145	Processing of complex N-glycans in IgG Fc-region is affected by core fucosylation. <i>MAbs</i> , 2015, 7, 863-870.	5.2	50
146	Antiviral Monoclonal Antibodies: Can They Be More Than Simple Neutralizing Agents?. <i>Trends in Microbiology</i> , 2015, 23, 653-665.	7.7	97
147	Molecular pharming™ foot in the FDA™ door: Protalix™ trailblazing story. <i>Biotechnology Letters</i> , 2015, 37, 2147-2150.	2.2	53

#	ARTICLE	IF	CITATIONS
148	Fc receptors and their influence on efficacy of therapeutic antibodies for treatment of viral diseases. Expert Review of Anti-Infective Therapy, 2015, 13, 1351-1360.	4.4	34
149	Codon-optimized filovirus DNA vaccines delivered by intramuscular electroporation protect cynomolgus macaques from lethal Ebola and Marburg virus challenges. Human Vaccines and Immunotherapeutics, 2015, 11, 1991-2004.	3.3	61
150	Post-exposure prophylaxis against Ebola virus disease with experimental antiviral agents: a case-series of health-care workers. Lancet Infectious Diseases, The, 2015, 15, 1300-1304.	9.1	64
151	Cytokines and viral hemorrhagic fever: potential for therapeutic intervention. Future Virology, 2015, 10, 547-557.	1.8	5
152	<i>Ebola virus</i> comparative genomics. FEMS Microbiology Reviews, 2015, 39, 764-778.	8.6	54
153	Emergence of Ebola Virus Escape Variants in Infected Nonhuman Primates Treated with the MB-003 Antibody Cocktail. Cell Reports, 2015, 12, 2111-2120.	6.4	68
154	Exploiting mobile RNA silencing for crop improvement. American Journal of Botany, 2015, 102, 1399-1400.	1.7	10
155	Ebola Virus Infection: Overview and Update on Prevention and Treatment. Infectious Diseases and Therapy, 2015, 4, 365-390.	4.0	33
156	Immunotherapy for Infectious Diseases: Past, Present, and Future. Immunological Investigations, 2015, 44, 731-737.	2.0	22
157	In silico prediction of ebolavirus RNA polymerase inhibition by specific combinations of approved nucleotide analogues. Journal of Clinical Virology, 2015, 73, 89-94.	3.1	5
158	Sanctuary Sites: What Lies Behind Ebola Eye Infections, Sexual Transmission, and Relapses. Health Security, 2015, 13, 396-398.	1.8	2
159	A SARS-like cluster of circulating bat coronaviruses shows potential for human emergence. Nature Medicine, 2015, 21, 1508-1513.	30.7	753
160	Chemical and Structural Aspects of Ebola Virus Entry Inhibitors. ACS Infectious Diseases, 2015, 1, 42-52.	3.8	32
161	Development of therapeutics for treatment of Ebola virus infection. Microbes and Infection, 2015, 17, 109-117.	1.9	40
162	Guidelines for treatment of patients with Ebola Virus Diseases are urgently needed. International Journal of Infectious Diseases, 2015, 30, 85-86.	3.3	5
163	Ebola virus (EBOV) infection: Therapeutic strategies. Biochemical Pharmacology, 2015, 93, 1-10.	4.4	69
164	Ebola virus disease: a highly fatal infectious disease reemerging in West Africa. Microbes and Infection, 2015, 17, 84-97.	1.9	35
165	Molecular Characterization of the Monoclonal Antibodies Composing ZMAb: A Protective Cocktail Against Ebola Virus. Scientific Reports, 2014, 4, 6881.	3.3	90

#	ARTICLE	IF	CITATIONS
166	Potential and Emerging Treatment Options for Ebola Virus Disease. <i>Annals of Pharmacotherapy</i> , 2015, 49, 196-206.	1.9	94
167	Treatment of Ebola virus disease. <i>Intensive Care Medicine</i> , 2015, 41, 115-117.	8.2	32
168	Tissue and cellular tropism, pathology and pathogenesis of Ebola and Marburg viruses. <i>Journal of Pathology</i> , 2015, 235, 153-174.	4.5	261
169	Preparing for Serious Communicable Diseases in the United States: What the Ebola Virus Epidemic Has Taught Us. <i>Microbiology Spectrum</i> , 2016, 4, .	3.0	3
170	West Africa 2013: Re-examining Ebola. <i>Microbiology Spectrum</i> , 2016, 4, .	3.0	16
171	Current and Future Diagnostic Tests for Ebola Virus Disease. <i>Journal of Pharmacy and Pharmaceutical Sciences</i> , 2016, 19, 530.	2.1	4
172	Ebola viral disease in West Africa: a threat to global health, economy and political stability. <i>Journal of Public Health in Africa</i> , 2016, 7, 534.	0.4	56
173	Ebola virus “ from neglected threat to global emergency state. <i>Revista Da Associação Médica Brasileira</i> , 2016, 62, 458-467.	0.7	1
174	Advancements in the Therapy of Ebola Virus Disease. <i>Pediatric Infectious Diseases Open Access</i> , 2016, 01, .	0.0	0
175	Broadly neutralizing antibodies for therapy of viral infections. <i>Antibody Technology Journal</i> , 2016, , 1.	0.0	2
176	Ebola Virus Persistence in Semen Ex Vivo. <i>Emerging Infectious Diseases</i> , 2016, 22, 289-291.	4.3	21
178	Experimental Treatment with Favipiravir for Ebola Virus Disease (the JIKI Trial): A Historically Controlled, Single-Arm Proof-of-Concept Trial in Guinea. <i>PLoS Medicine</i> , 2016, 13, e1001967.	8.4	382
179	Clomiphene and Its Isomers Block Ebola Virus Particle Entry and Infection with Similar Potency: Potential Therapeutic Implications. <i>Viruses</i> , 2016, 8, 206.	3.3	40
180	Integrated Computational Approach for Virtual Hit Identification against Ebola Viral Proteins VP35 and VP40. <i>International Journal of Molecular Sciences</i> , 2016, 17, 1748.	4.1	37
181	Immunological Characterization of Plant-Based HIV-1 Gag/Dgp41 Virus-Like Particles. <i>PLoS ONE</i> , 2016, 11, e0151842.	2.5	20
182	Adaptive Immunity. , 2016, , 57-69.		9
183	Transient Glyco-Engineering to Produce Recombinant IgA1 with Defined N- and O-Glycans in Plants. <i>Frontiers in Plant Science</i> , 2016, 7, 18.	3.6	63
184	The potential of plants as a system for the development and production of human biologics. <i>F1000Research</i> , 2016, 5, 912.	1.6	110

#	ARTICLE	IF	CITATIONS
185	An Outbreak of Ebola Virus Disease in the Lassa Fever Zone. <i>Journal of Infectious Diseases</i> , 2016, 214, S110-S121.	4.0	34
186	Mapping of Ebolavirus Neutralization by Monoclonal Antibodies in the ZMapp Cocktail Using Cryo-Electron Tomography and Studies of Cellular Entry. <i>Journal of Virology</i> , 2016, 90, 7618-7627.	3.4	32
187	Dimeric Fc γ 3R Ectodomains as Probes of the Fc Receptor Function of Anti-Influenza Virus IgG. <i>Journal of Immunology</i> , 2016, 197, 1507-1516.	0.8	90
188	Production of a tumour-targeting antibody with a human-compatible glycosylation profile in <i>N. benthamiana</i> hairy root cultures. <i>Biotechnology Journal</i> , 2016, 11, 1209-1220.	3.5	29
189	Oral Delivery of Protein Drugs Bioencapsulated in Plant Cells. <i>Molecular Therapy</i> , 2016, 24, 1342-1350.	8.2	73
191	Two-mAb cocktail protects macaques against the Makona variant of Ebola virus. <i>Science Translational Medicine</i> , 2016, 8, 329ra33.	12.4	78
192	Bioengineering of Tobacco Mosaic Virus to Create a Non-Infectious Positive Control for Ebola Diagnostic Assays. <i>Scientific Reports</i> , 2016, 6, 23803.	3.3	20
193	Molecular determinants of human neutralizing antibodies isolated from a patient infected with Zika virus. <i>Science Translational Medicine</i> , 2016, 8, 369ra179.	12.4	194
194	Functional screening for anti-CMV biologics identifies a broadly neutralizing epitope of an essential envelope protein. <i>Nature Communications</i> , 2016, 7, 13627.	12.8	21
195	Plant Structure and Specificity – Challenges and Sample Preparation Considerations for Proteomics. <i>Advances in Experimental Medicine and Biology</i> , 2016, 919, 63-81.	1.6	6
196	Biomufacturing of protective antibodies and other therapeutics in edible plant tissues for oral applications. <i>Plant Biotechnology Journal</i> , 2016, 14, 1791-1799.	8.3	29
197	Passive immunisation, an old idea revisited: Basic principles and application to modern animal production systems. <i>Veterinary Immunology and Immunopathology</i> , 2016, 174, 50-63.	1.2	39
198	Glycopeptide Antibiotics Potently Inhibit Cathepsin L in the Late Endosome/Lysosome and Block the Entry of Ebola Virus, Middle East Respiratory Syndrome Coronavirus (MERS-CoV), and Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV). <i>Journal of Biological Chemistry</i> , 2016, 291, 9218-9232.	3.4	230
199	Monoclonal antibody therapy for Junin virus infection. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 4458-4463.	7.1	50
200	Large-Scale Screening and Identification of Novel Ebola Virus and Marburg Virus Entry Inhibitors. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 4471-4481.	3.2	52
201	Analysis of Ebola virus polymerase domains to find strain-specific differences and to gain insight on their pathogenicity. <i>VirusDisease</i> , 2016, 27, 242-250.	2.0	4
202	Synergistic Neutralization of Pertussis Toxin by a Bispecific Antibody <i>In Vitro</i> and <i>In Vivo</i> . <i>Vaccine Journal</i> , 2016, 23, 851-862.	3.1	14
203	A –Trojan horse–bispecific-antibody strategy for broad protection against ebolaviruses. <i>Science</i> , 2016, 354, 350-354.	12.6	101

#	ARTICLE	IF	CITATIONS
204	Maladie À virus Ebola: actualit�s th�rapeutiques. Journal Des Anti-infectieux, 2016, 18, 117-125.	0.1	2
205	Ebola virus disease and critical illness. Critical Care, 2016, 20, 217.	5.8	97
206	Monoclonal antibodies for the treatment of Ebola virus disease. Expert Opinion on Investigational Drugs, 2016, 25, 1325-1335.	4.1	34
207	Adeno-Associated Virus Serotype 9-Expressed ZMapp in Mice Confers Protection Against Systemic and Airway-Acquired Ebola Virus Infection. Journal of Infectious Diseases, 2016, 214, 1975-1979.	4.0	14
208	A Randomized, Controlled Trial of ZMapp for Ebola Virus Infection. New England Journal of Medicine, 2016, 375, 1448-1456.	27.0	429
209	Comparison of the Aerosol Stability of 2 Strains of Zaire ebolavirus From the 1976 and 2013 Outbreaks. Journal of Infectious Diseases, 2016, 214, S290-S293.	4.0	20
210	Efficacy of Vesicular Stomatitis Virus-Ebola Virus Postexposure Treatment in Rhesus Macaques Infected With Ebola Virus Makona. Journal of Infectious Diseases, 2016, 214, S360-S366.	4.0	62
211	Glycoengineering of plants yields glycoproteins with polysialylation and other defined N-glycoforms. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 9404-9406.	7.1	32
212	Health-Care Workers' Perspectives on Ebola Virus Vaccine: A Focus Group and In-Depth Interview Interventional Study. American Journal of Tropical Medicine and Hygiene, 2016, 95, 654-662.	1.4	10
213	MERS-CoV spike protein: Targets for vaccines and therapeutics. Antiviral Research, 2016, 133, 165-177.	4.1	94
214	Preliminary Evaluation of the Effect of Investigational Ebola Virus Disease Treatments on Viral Genome Sequences. Journal of Infectious Diseases, 2016, 214, S333-S341.	4.0	11
215	Converting monoclonal antibody-based immunotherapies from passive to active: bringing immune complexes into play. Emerging Microbes and Infections, 2016, 5, 1-9.	6.5	36
216	Engineering of complex protein sialylation in plants. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 9498-9503.	7.1	88
217	Passive Immunotherapy: Assessment of Convalescent Serum Against Ebola Virus Makona Infection in Nonhuman Primates. Journal of Infectious Diseases, 2016, 214, S367-S374.	4.0	36
218	Molecular mechanisms of Ebola pathogenesis. Journal of Leukocyte Biology, 2016, 100, 889-904.	3.3	31
219	An Ebola Virus-Like Particle-Based Reporter System Enables Evaluation of Antiviral Drugs <i>In Vivo</i> under Non-Biosafety Level 4 Conditions. Journal of Virology, 2016, 90, 8720-8728.	3.4	15
220	Epidemiology and Management of the 2013-16 West African Ebola Outbreak. Annual Review of Virology, 2016, 3, 147-171.	6.7	28
221	Plant factories for the production of monoclonal antibodies. Biochemistry (Moscow), 2016, 81, 1118-1135.	1.5	19

#	ARTICLE	IF	CITATIONS
222	Immunogenomic engineering of a plug-and-(dis)play hybridoma platform. <i>Nature Communications</i> , 2016, 7, 12535.	12.8	50
223	Treatment with hyperimmune equine immunoglobulin or immunoglobulin fragments completely protects rodents from Ebola virus infection. <i>Scientific Reports</i> , 2016, 6, 24179.	3.3	33
224	Plant-produced biopharmaceuticals: A case of technical developments driving clinical deployment. <i>Science</i> , 2016, 353, 1237-1240.	12.6	159
225	Host-Primed Ebola Virus GP Exposes a Hydrophobic NPC1 Receptor-Binding Pocket, Revealing a Target for Broadly Neutralizing Antibodies. <i>MBio</i> , 2016, 7, e02154-15.	4.1	86
226	Pathogenicity Comparison Between the Kikwit and Makona Ebola Virus Variants in Rhesus Macaques. <i>Journal of Infectious Diseases</i> , 2016, 214, S281-S289.	4.0	30
227	Filovirus proteins for antiviral drug discovery: A structure/function analysis of surface glycoproteins and virus entry. <i>Antiviral Research</i> , 2016, 135, 1-14.	4.1	33
228	Blueprints for green biotech: development and application of standards for plant synthetic biology. <i>Biochemical Society Transactions</i> , 2016, 44, 702-708.	3.4	8
229	Engineered Mesenchymal Cells Improve Passive Immune Protection Against Lethal Venezuelan Equine Encephalitis Virus Exposure. <i>Stem Cells Translational Medicine</i> , 2016, 5, 1026-1035.	3.3	16
230	Post-exposure treatment of Ebola virus disease in guinea pigs using EBOTAb, an ovine antibody-based therapeutic. <i>Scientific Reports</i> , 2016, 6, 30497.	3.3	11
231	Enabling Rapid Response to the 2014â€“2016 Ebola Epidemic: The Experience and the Results of the National Institute for Infectious Diseases Lazzaro Spallanzani. <i>Advances in Experimental Medicine and Biology</i> , 2016, 972, 103-122.	1.6	2
232	Potent neutralizing monoclonal antibodies against Ebola virus infection. <i>Scientific Reports</i> , 2016, 6, 25856.	3.3	46
233	Production of Potent Fully Human Polyclonal Antibodies against Ebola Zaire Virus in Transchromosomal Cattle. <i>Scientific Reports</i> , 2016, 6, 24897.	3.3	35
234	Inhibition of preS1-hepatocyte interaction by an array of recombinant human antibodies from naturally recovered individuals. <i>Scientific Reports</i> , 2016, 6, 21240.	3.3	18
235	Discovery of an antibody for pan-ebolavirus therapy. <i>Scientific Reports</i> , 2016, 6, 20514.	3.3	83
236	Modelling Ebola virus dynamics: Implications for therapy. <i>Antiviral Research</i> , 2016, 135, 62-73.	4.1	26
237	Antiviral therapeutics for the treatment of Ebola virus infection. <i>Current Opinion in Pharmacology</i> , 2016, 30, 138-143.	3.5	17
238	Modulating Antibody Functionality in Infectious Disease and Vaccination. <i>Trends in Molecular Medicine</i> , 2016, 22, 969-982.	6.7	71
239	Structures of Ebola virus GP and sGP in complex with therapeutic antibodies. <i>Nature Microbiology</i> , 2016, 1, 16128.	13.3	92

#	ARTICLE	IF	CITATIONS
240	Fighting Infection in a Globalized World. <i>Cell</i> , 2016, 167, 583-585.	28.9	1
241	Hitting Ebola, to the power of two. <i>Science</i> , 2016, 354, 284-285.	12.6	4
242	Rescue of non-human primates from advanced Sudan ebolavirus infection with lipid encapsulated siRNA. <i>Nature Microbiology</i> , 2016, 1, 16142.	13.3	52
245	A web-based resource for designing therapeutics against Ebola Virus. <i>Scientific Reports</i> , 2016, 6, 24782.	3.3	14
246	Ebola Virus Disease: Therapeutic and Potential Preventative Opportunities. <i>Microbiology Spectrum</i> , 2016, 4, .	3.0	1
247	Bispecific Antibody Affords Complete Post-Exposure Protection of Mice from Both Ebola (Zaire) and Sudan Viruses. <i>Scientific Reports</i> , 2016, 6, 19193.	3.3	27
248	Development and characterization of monoclonal antibodies to Ebola virus glycoprotein. <i>Moscow University Biological Sciences Bulletin</i> , 2016, 71, 24-28.	0.7	1
249	Cell-targeting antibodies in immunity to Ebola. <i>Pathogens and Disease</i> , 2016, 74, ftw021.	2.0	11
250	Antiviral Therapy. , 2016, , 271-287.		22
251	Single-dose treatment with a humanized neutralizing antibody affords full protection of a human transgenic mouse model from lethal Middle East respiratory syndrome (MERS)-coronavirus infection. <i>Antiviral Research</i> , 2016, 132, 141-148.	4.1	46
252	Antibody Treatment of Ebola and Sudan Virus Infection via a Uniquely Exposed Epitope within the Glycoprotein Receptor-Binding Site. <i>Cell Reports</i> , 2016, 15, 1514-1526.	6.4	80
253	Conducting clinical trials in outbreak settings: Points to consider. <i>Clinical Trials</i> , 2016, 13, 92-95.	1.6	35
254	The 2014â€“2015 Ebola outbreak in West Africa: Hands On. <i>Antimicrobial Resistance and Infection Control</i> , 2016, 5, .	4.1	55
255	A plant-expressed conjugate vaccine breaks CD4⁺ tolerance and induces potent immunity against metastatic Her2⁺ breast cancer. <i>Oncolmmunology</i> , 2016, 5, e1166323.	4.6	36
256	New monoclonal antibodies to the Ebola virus glycoprotein: Identification and analysis of the amino acid sequence of the variable domains. <i>Doklady Biochemistry and Biophysics</i> , 2016, 467, 117-120.	0.9	3
257	The Ethics of Infection Challenges in Primates. <i>Hastings Center Report</i> , 2016, 46, 20-26.	1.0	14
258	Chronic treatment of (+)-methamphetamine-induced locomotor effects in rats using one or a combination of two high affinity anti-methamphetamine monoclonal antibodies. <i>Human Vaccines and Immunotherapeutics</i> , 2016, 12, 2240-2248.	3.3	7
259	Integrated sequence and immunology filovirus database at Los Alamos. <i>Database: the Journal of Biological Databases and Curation</i> , 2016, 2016, baw047.	3.0	3

#	ARTICLE	IF	CITATIONS
260	Purification of a recombinant glutathione transferase from the causative agent of hydatidosis, <i>Echinococcus granulosus</i> . <i>Biochemistry and Molecular Biology Education</i> , 2016, 44, 28-37.	1.2	4
261	Cross-Reactive and Potent Neutralizing Antibody Responses in Human Survivors of Natural Ebolavirus Infection. <i>Cell</i> , 2016, 164, 392-405.	28.9	160
263	Ebola Viral Glycoprotein Bound to Its Endosomal Receptor Niemann-Pick C1. <i>Cell</i> , 2016, 164, 258-268.	28.9	226
264	Progression of Ebola Therapeutics During the 2014-2015 Outbreak. <i>Trends in Molecular Medicine</i> , 2016, 22, 164-173.	6.7	67
265	CHO cell production and sequence improvement in the 13C6FR1 anti-Ebola antibody. <i>MAbs</i> , 2016, 8, 347-357.	5.2	17
266	Droplet-based microfluidics in drug discovery, transcriptomics and high-throughput molecular genetics. <i>Lab on A Chip</i> , 2016, 16, 1314-1331.	6.0	295
267	Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys. <i>Nature</i> , 2016, 531, 381-385.	27.8	1,245
268	The use of GRADE approach in systematic reviews of animal studies. <i>Journal of Evidence-Based Medicine</i> , 2016, 9, 98-104.	2.4	40
269	Promises and pitfalls for recombinant oligoclonal antibodies-based therapeutics in cancer and infectious disease. <i>Current Opinion in Immunology</i> , 2016, 40, 51-61.	5.5	12
270	The case for plant-made veterinary immunotherapeutics. <i>Biotechnology Advances</i> , 2016, 34, 597-604.	11.7	46
271	Isolation of potent neutralizing antibodies from a survivor of the 2014 Ebola virus outbreak. <i>Science</i> , 2016, 351, 1078-1083.	12.6	194
272	Ebola Virus Infection: Review of the Pharmacokinetic and Pharmacodynamic Properties of Drugs Considered for Testing in Human Efficacy Trials. <i>Clinical Pharmacokinetics</i> , 2016, 55, 907-923.	3.5	135
273	Antibody therapeutics for Ebola virus disease. <i>Current Opinion in Virology</i> , 2016, 17, 45-49.	5.4	45
274	Chimeric Filoviruses for Identification and Characterization of Monoclonal Antibodies. <i>Journal of Virology</i> , 2016, 90, 3890-3901.	3.4	41
275	Implications of plant glycans in the development of innovative vaccines. <i>Expert Review of Vaccines</i> , 2016, 15, 915-925.	4.4	26
276	Protective monotherapy against lethal Ebola virus infection by a potently neutralizing antibody. <i>Science</i> , 2016, 351, 1339-1342.	12.6	370
277	Antibody Production in Plants and Green Algae. <i>Annual Review of Plant Biology</i> , 2016, 67, 669-701.	18.7	52
278	Structural and molecular basis for Ebola virus neutralization by protective human antibodies. <i>Science</i> , 2016, 351, 1343-1346.	12.6	176

#	ARTICLE	IF	CITATIONS
279	SARS-like WIV1-CoV poised for human emergence. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 3048-3053.	7.1	373
280	Matrix-M adjuvant enhances antibody, cellular and protective immune responses of a Zaire Ebola/Makona virus glycoprotein (GP) nanoparticle vaccine in mice. Vaccine, 2016, 34, 1927-1935.	3.8	106
281	Development of a Cost-effective Ovine Polyclonal Antibody-Based Product, EBOTAb, to Treat Ebola Virus Infection. Journal of Infectious Diseases, 2016, 213, 1124-1133.	4.0	24
282	Cell-cell contact promotes Ebola virus GP-mediated infection. Virology, 2016, 488, 202-215.	2.4	10
283	Determination and Therapeutic Exploitation of Ebola Virus Spontaneous Mutation Frequency. Journal of Virology, 2016, 90, 2345-2355.	3.4	17
284	Characterization of the inhibitory effect of an extract of <i>Prunella vulgaris</i> on Ebola virus glycoprotein (GP)-mediated virus entry and infection. Antiviral Research, 2016, 127, 20-31.	4.1	41
285	Specific neutralizing response in plasma from convalescent patients of Ebola Virus Disease against the West Africa Makona variant of Ebola virus. Virus Research, 2016, 213, 224-229.	2.2	23
286	Evaluation of Convalescent Plasma for Ebola Virus Disease in Guinea. New England Journal of Medicine, 2016, 374, 33-42.	27.0	457
287	Antibody-Based Biologics and Their Promise to Combat <i>Staphylococcus aureus</i> Infections. Trends in Pharmacological Sciences, 2016, 37, 231-241.	8.7	93
288	Pan-ebolavirus and Pan-filovirus Mouse Monoclonal Antibodies: Protection against Ebola and Sudan Viruses. Journal of Virology, 2016, 90, 266-278.	3.4	92
289	Macaque Monoclonal Antibodies Targeting Novel Conserved Epitopes within Filovirus Glycoprotein. Journal of Virology, 2016, 90, 279-291.	3.4	72
290	Development and Characterization of a Guinea Pig-Adapted Sudan Virus. Journal of Virology, 2016, 90, 392-399.	3.4	42
291	The Use of Ebola Convalescent Plasma to Treat Ebola Virus Disease in Resource-Constrained Settings: A Perspective From the Field. Clinical Infectious Diseases, 2016, 62, 69-74.	5.8	84
292	<i>Nicotiana benthamiana</i> cathepsin B displays distinct enzymatic features which differ from its human relative and aleurain-like protease. Biochimie, 2016, 122, 119-125.	2.6	26
293	Gain-of-Function Research and the Relevance to Clinical Practice. Journal of Infectious Diseases, 2016, 213, 1364-1369.	4.0	10
294	Flavonoids as Multi-target Inhibitors for Proteins Associated with Ebola Virus: In Silico Discovery Using Virtual Screening and Molecular Docking Studies. Interdisciplinary Sciences, Computational Life Sciences, 2016, 8, 132-141.	3.6	65
295	Prediction of Epitope-Based Peptides for Vaccine Development from Coat Proteins GP2 and VP24 of Ebola Virus Using Immunoinformatics. International Journal of Peptide Research and Therapeutics, 2016, 22, 119-133.	1.9	15
296	Ebolavirus Glycoprotein Directs Fusion through NPC1 Endolysosomes. Journal of Virology, 2016, 90, 605-610.	3.4	67

#	ARTICLE	IF	CITATIONS
298	Anti-Ebola therapies based on monoclonal antibodies: current state and challenges ahead. <i>Critical Reviews in Biotechnology</i> , 2017, 37, 53-68.	9.0	21
299	Label free checkerboard assay to determine overlapping epitopes of Ebola virus VP-40 antibodies using surface plasmon resonance. <i>Journal of Immunological Methods</i> , 2017, 442, 42-48.	1.4	10
300	Immunobiology of Ebola and Lassa virus infections. <i>Nature Reviews Immunology</i> , 2017, 17, 195-207.	22.7	95
301	Use of broadly neutralizing antibodies for HIV prevention. <i>Immunological Reviews</i> , 2017, 275, 296-312.	6.0	131
302	A Bioengineered Positive Control for Rapid Detection of the Ebola Virus by Reverse Transcription Loop-Mediated Isothermal Amplification (RT-LAMP). <i>ACS Biomaterials Science and Engineering</i> , 2017, 3, 452-459.	5.2	9
303	First Newborn Baby to Receive Experimental Therapies Survives Ebola Virus Disease. <i>Journal of Infectious Diseases</i> , 2017, 215, jiw493.	4.0	104
304	Will There Be a Cure for Ebola?. <i>Annual Review of Pharmacology and Toxicology</i> , 2017, 57, 329-348.	9.4	40
305	Selective inhibition of Ebola entry with selective estrogen receptor modulators by disrupting the endolysosomal calcium. <i>Scientific Reports</i> , 2017, 7, 41226.	3.3	41
306	Discovery and Synthesis of a Phosphoramidate Prodrug of a Pyrrolo[2,1- <i>f</i>][triazin-4-amino] Adenine <i>C</i> -Nucleoside (GS-5734) for the Treatment of Ebola and Emerging Viruses. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 1648-1661.	6.4	547
307	Ebola and Marburg: Out of Africa. , 2017, , 131-154.		0
308	Candidate medical countermeasures targeting Ebola virus cell entry. <i>Future Virology</i> , 2017, 12, 119-140.	1.8	1
309	The papain-like cysteine proteinases NbCysP6 and NbCysP7 are highly processive enzymes with substrate specificities complementary to <i>Nicotiana benthamiana</i> cathepsin B. <i>Biochimica Et Biophysica Acta - Proteins and Proteomics</i> , 2017, 1865, 444-452.	2.3	28
310	A Sensitive in Vitro High-Throughput Screen To Identify Pan-filoviral Replication Inhibitors Targeting the VP35-NP Interface. <i>ACS Infectious Diseases</i> , 2017, 3, 190-198.	3.8	22
311	Ebola virus infection induces autoimmunity against dsDNA and HSP60. <i>Scientific Reports</i> , 2017, 7, 42147.	3.3	14
312	Chemically Modified Human Serum Albumin Potently Blocks Entry of Ebola Pseudoviruses and Viruslike Particles. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	20
313	Offering patients more: how the West Africa Ebola outbreak can shape innovation in therapeutic research for emerging and epidemic infections. <i>Philosophical Transactions of the Royal Society B: Biological Sciences</i> , 2017, 372, 20160294.	4.0	10
314	An inter-residue network model to identify mutational-constrained regions on the Ebola coat glycoprotein. <i>Scientific Reports</i> , 2017, 7, 45886.	3.3	8
315	Cooperativity Enables Non-neutralizing Antibodies to Neutralize Ebolavirus. <i>Cell Reports</i> , 2017, 19, 413-424.	6.4	66

#	ARTICLE	IF	CITATIONS
316	Cell genetic engineering: Transmission genetics of plants. <i>Cytology and Genetics</i> , 2017, 51, 103-107.	0.5	3
317	How to treat Ebola virus infections? A lesson from the field. <i>Current Opinion in Virology</i> , 2017, 24, 9-15.	5.4	15
318	Emerging and Re-emerging Viral Infections. <i>Advances in Experimental Medicine and Biology</i> , 2017, , .	1.6	2
319	Effect of temperature post viral vector inoculation on the amount of hemagglutinin transiently expressed in <i>Nicotiana benthamiana</i> leaves. <i>Journal of Bioscience and Bioengineering</i> , 2017, 124, 346-350.	2.2	17
320	125 years of virology and ascent of biotechnologies based on viral expressio. <i>Cytology and Genetics</i> , 2017, 51, 87-102.	0.5	7
321	Insights from clinical research completed during the west Africa Ebola virus disease epidemic. <i>Lancet Infectious Diseases, The</i> , 2017, 17, e280-e292.	9.1	69
322	Media development for large scale <i>Agrobacterium tumefaciens</i> culture. <i>Biotechnology Progress</i> , 2017, 33, 1218-1225.	2.6	7
323	Antibodies from a Human Survivor Define Sites of Vulnerability for Broad Protection against Ebolaviruses. <i>Cell</i> , 2017, 169, 878-890.e15.	28.9	145
324	Immunization-Elicited Broadly Protective Antibody Reveals Ebolavirus Fusion Loop as a Site of Vulnerability. <i>Cell</i> , 2017, 169, 891-904.e15.	28.9	103
325	Exploring Site-Specific N-Glycosylation of HEK293 and Plant-Produced Human IgA Isotypes. <i>Journal of Proteome Research</i> , 2017, 16, 2560-2570.	3.7	41
326	T-cell-dependent mechanisms promote Ebola VLP-induced antibody responses, but are dispensable for vaccine-mediated protection. <i>Emerging Microbes and Infections</i> , 2017, 6, 1-9.	6.5	13
328	Clinical Management of Patients with Ebola Virus Disease in High-Resource Settings. <i>Current Topics in Microbiology and Immunology</i> , 2017, 411, 115-137.	1.1	3
329	Effects of plant density on recombinant hemagglutinin yields in an <i>Agrobacterium</i> mediated transient gene expression system using <i>Nicotiana benthamiana</i> plants. <i>Biotechnology and Bioengineering</i> , 2017, 114, 1762-1770.	3.3	15
330	Successful post-exposure prophylaxis of Ebola infected non-human primates using Ebola glycoprotein-specific equine IgG. <i>Scientific Reports</i> , 2017, 7, 41537.	3.3	14
331	Therapeutic treatment of Marburg and Ravn virus infection in nonhuman primates with a human monoclonal antibody. <i>Science Translational Medicine</i> , 2017, 9, .	12.4	64
332	Expression of the VP40 antigen from the Zaire ebolavirus in tobacco plants. <i>Planta</i> , 2017, 246, 123-132.	3.2	17
333	Antibodies from plants for bionanomaterials. <i>Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology</i> , 2017, 9, e1462.	6.1	21
334	Antibody-dependent-cellular-cytotoxicity-inducing antibodies significantly affect the post-exposure treatment of Ebola virus infection. <i>Scientific Reports</i> , 2017, 7, 45552.	3.3	80

#	ARTICLE	IF	CITATIONS
335	The ongoing evolution of antibody-based treatments for Ebola virus infection. <i>Immunotherapy</i> , 2017, 9, 435-450.	2.0	20
336	Crystal Structure of a Homogeneous IgG-Fc Glycoform with the N-Glycan Designed to Maximize the Antibody Dependent Cellular Cytotoxicity. <i>ACS Chemical Biology</i> , 2017, 12, 1335-1345.	3.4	31
337	Expression of an immunogenic LTB-based chimeric protein targeting Zaire ebolavirus epitopes from GP1 in plant cells. <i>Plant Cell Reports</i> , 2017, 36, 355-365.	5.6	25
338	The Pathogenesis of Ebola Virus Disease. <i>Annual Review of Pathology: Mechanisms of Disease</i> , 2017, 12, 387-418.	22.4	266
339	Recombinant Plant Engineering for Immunotherapeutic Production. <i>Current Molecular Biology Reports</i> , 2017, 3, 306-316.	1.6	3
340	In Vivo Production of Monoclonal Antibodies by Gene Transfer via Electroporation Protects against Lethal Influenza and Ebola Infections. <i>Molecular Therapy - Methods and Clinical Development</i> , 2017, 7, 74-82.	4.1	24
341	Discovering Drugs for the Treatment of Ebola Virus. <i>Current Treatment Options in Infectious Diseases</i> , 2017, 9, 299-317.	1.9	51
343	Clinical Evaluation of Ebola Virus Disease Therapeutics. <i>Trends in Molecular Medicine</i> , 2017, 23, 820-830.	6.7	17
344	Rationale for Adjunctive Therapies for Pediatric Sepsis Induced Multiple Organ Failure. <i>Pediatric Clinics of North America</i> , 2017, 64, 1071-1088.	1.8	13
345	Identification of broadly neutralizing monoclonal antibodies against Crimean-Congo hemorrhagic fever virus. <i>Antiviral Research</i> , 2017, 146, 112-120.	4.1	40
346	Combinatorial peptide-based epitope mapping from Ebola virus DNA vaccines and infections reveals residue-level determinants of antibody binding. <i>Human Vaccines and Immunotherapeutics</i> , 2017, 13, 2953-2966.	3.3	4
347	Windows of opportunity for Ebola virus infection treatment and vaccination. <i>Scientific Reports</i> , 2017, 7, 8975.	3.3	34
348	Antibody therapies for the prevention and treatment of viral infections. <i>Npj Vaccines</i> , 2017, 2, 19.	6.0	156
349	Synthesis of C-glycosylated Octaketide Anthraquinones in <i>Nicotiana benthamiana</i> by Using a Multispecies-Based Biosynthetic Pathway. <i>ChemBioChem</i> , 2017, 18, 1893-1897.	2.6	24
350	A heterologous prime-boost Ebola virus vaccine regimen induces durable neutralizing antibody response and prevents Ebola virus-like particle entry in mice. <i>Antiviral Research</i> , 2017, 145, 54-59.	4.1	10
351	Neutralizing the Threat: Pan-Ebolavirus Antibodies Close the Loop. <i>Trends in Molecular Medicine</i> , 2017, 23, 669-671.	6.7	12
352	Dengue Virus Evades AAV-Mediated Neutralizing Antibody Prophylaxis in Rhesus Monkeys. <i>Molecular Therapy</i> , 2017, 25, 2323-2331.	8.2	9
354	Using transgenic plants and modified plant viruses for the development of treatments for human diseases. <i>Current Opinion in Virology</i> , 2017, 26, 81-89.	5.4	42

#	ARTICLE	IF	CITATIONS
355	Production of Functional Anti-Ebola Antibodies in <i>Pichia pastoris</i> . <i>ACS Synthetic Biology</i> , 2017, 6, 2183-2190.	3.8	15
356	Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, E7348-E7357.	7.1	944
357	A review on the antagonist Ebola: A prophylactic approach. <i>Biomedicine and Pharmacotherapy</i> , 2017, 96, 1513-1526.	5.6	13
358	Middle East Respiratory Syndrome and Severe Acute Respiratory Syndrome: Current Therapeutic Options and Potential Targets for Novel Therapies. <i>Drugs</i> , 2017, 77, 1935-1966.	10.9	156
359	Human monoclonal antibodies as candidate therapeutics against emerging viruses. <i>Frontiers of Medicine</i> , 2017, 11, 462-470.	3.4	38
360	N-glycan structures and downstream mannose-phosphorylation of plant recombinant human alpha-L-iduronidase: toward development of enzyme replacement therapy for mucopolysaccharidosis I. <i>Plant Molecular Biology</i> , 2017, 95, 593-606.	3.9	8
361	Post-exposure treatment of non-human primates lethally infected with Ebola virus with EBOTAb, a purified ovine IgG product. <i>Scientific Reports</i> , 2017, 7, 4099.	3.3	11
362	3D Printing of Regenerated Silk Fibroin and Antibody-Containing Microstructures via Multiphoton Lithography. <i>ACS Biomaterials Science and Engineering</i> , 2017, 3, 2064-2075.	5.2	39
363	Bispecific antibodies for viral immunotherapy. <i>Human Vaccines and Immunotherapeutics</i> , 2017, 13, 836-842.	3.3	22
364	Favipiravir Pharmacokinetics in Nonhuman Primates and Insights for Future Efficacy Studies of Hemorrhagic Fever Viruses. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	59
365	The roles of ebolavirus glycoproteins in viral pathogenesis. <i>Virologica Sinica</i> , 2017, 32, 3-15.	3.0	17
366	De Novo MS/MS Sequencing of Native Human Antibodies. <i>Journal of Proteome Research</i> , 2017, 16, 45-54.	3.7	41
367	Understanding bat SARS-like coronaviruses for the preparation of future coronavirus outbreaks – Implications for coronavirus vaccine development. <i>Human Vaccines and Immunotherapeutics</i> , 2017, 13, 186-189.	3.3	28
369	Toward an Effective Ebola Virus Vaccine. <i>Annual Review of Medicine</i> , 2017, 68, 371-386.	12.2	29
370	Reduced paucimannosidic N-glycan formation by suppression of a specific hexosaminidase from <i>Nicotiana benthamiana</i> . <i>Plant Biotechnology Journal</i> , 2017, 15, 197-206.	8.3	46
371	Evaluation of convalescent whole blood for treating Ebola Virus Disease in Freetown, Sierra Leone. <i>Journal of Infection</i> , 2017, 74, 302-309.	3.3	94
372	The early clinical development of Ebola virus treatments. <i>Expert Opinion on Investigational Drugs</i> , 2017, 26, 1-4.	4.1	3
373	Marburg- and Ebolaviruses. <i>Current Topics in Microbiology and Immunology</i> , 2017, , .	1.1	4

#	ARTICLE	IF	CITATIONS
374	Therapeutics Against Filovirus Infection. <i>Current Topics in Microbiology and Immunology</i> , 2017, 411, 263-290.	1.1	3
378	Broadly Neutralizing Antibodies. , 2017, , 3-21.		2
379	Disease Prevention: An Opportunity to Expand Edible Plant-Based Vaccines?. <i>Vaccines</i> , 2017, 5, 14.	4.4	34
380	Nattokinase: An Oral Antithrombotic Agent for the Prevention of Cardiovascular Disease. <i>International Journal of Molecular Sciences</i> , 2017, 18, 523.	4.1	108
381	A Perspective on the Development of Plant-Made Vaccines in the Fight against Ebola Virus. <i>Frontiers in Immunology</i> , 2017, 8, 252.	4.8	23
382	Antibody Engineering for Pursuing a Healthier Future. <i>Frontiers in Microbiology</i> , 2017, 8, 495.	3.5	111
383	Clinical Laboratory Values as Early Indicators of Ebola Virus Infection in Nonhuman Primates. <i>Emerging Infectious Diseases</i> , 2017, 23, 1316-1324.	4.3	13
384	The phosphatidylinositol-3-phosphate 5-kinase inhibitor apilimod blocks filoviral entry and infection. <i>PLoS Neglected Tropical Diseases</i> , 2017, 11, e0005540.	3.0	97
385	Analysis of patient data from laboratories during the Ebola virus disease outbreak in Liberia, April 2014 to March 2015. <i>PLoS Neglected Tropical Diseases</i> , 2017, 11, e0005804.	3.0	8
386	Na ⁺ -ve Human Antibody Libraries for Infectious Diseases. <i>Advances in Experimental Medicine and Biology</i> , 2017, 1053, 35-59.	1.6	14
387	Therapeutic Antibodies for Biodefense. <i>Advances in Experimental Medicine and Biology</i> , 2017, 1053, 173-205.	1.6	7
388	Synthetic Antibodies in Infectious Disease. <i>Advances in Experimental Medicine and Biology</i> , 2017, 1053, 79-98.	1.6	3
389	Immune Human Antibody Libraries for Infectious Diseases. <i>Advances in Experimental Medicine and Biology</i> , 2017, 1053, 61-78.	1.6	4
391	Sheik Humarr Khan. , 2017, , 39-47.		0
392	ZMapp. , 2017, , 49-62.		1
393	Plant-made Salmonella bacteriocins salmocins for control of Salmonella pathovars. <i>Scientific Reports</i> , 2018, 8, 4078.	3.3	31
394	Design and evaluation of bi- and trispecific antibodies targeting multiple filovirus glycoproteins. <i>Journal of Biological Chemistry</i> , 2018, 293, 6201-6211.	3.4	7
395	Three unrelated protease inhibitors enhance accumulation of pharmaceutical recombinant proteins in <i>Nicotiana benthamiana</i> . <i>Plant Biotechnology Journal</i> , 2018, 16, 1797-1810.	8.3	61

#	ARTICLE	IF	CITATIONS
396	A Pressure Test to Make 10 Molecules in 90 Days: External Evaluation of Methods to Engineer Biology. <i>Journal of the American Chemical Society</i> , 2018, 140, 4302-4316.	13.7	118
397	Importance of Neutralizing Monoclonal Antibodies Targeting Multiple Antigenic Sites on the Middle East Respiratory Syndrome Coronavirus Spike Glycoprotein To Avoid Neutralization Escape. <i>Journal of Virology</i> , 2018, 92, .	3.4	155
399	Ebola virus vaccination and the longevity of total versus neutralising antibody response“is it enough?. <i>Lancet Infectious Diseases</i> , The, 2018, 18, 699-700.	9.1	4
400	Chimeric 3â€™ flanking regions strongly enhance gene expression in plants. <i>Plant Biotechnology Journal</i> , 2018, 16, 1971-1982.	8.3	66
402	Post-exposure treatments for Ebola and Marburg virus infections. <i>Nature Reviews Drug Discovery</i> , 2018, 17, 413-434.	46.4	104
403	Passive immunotherapy of viral infections: 'super-antibodies' enter the fray. <i>Nature Reviews Immunology</i> , 2018, 18, 297-308.	22.7	220
404	Intramuscular Adeno-Associated Virus“Mediated Expression of Monoclonal Antibodies Provides 100% Protection Against Ebola Virus Infection in Mice. <i>Journal of Infectious Diseases</i> , 2018, 217, 916-925.	4.0	37
405	Versatile and on-demand biologics co-production in yeast. <i>Nature Communications</i> , 2018, 9, 77.	12.8	28
406	The Marburgvirus-Neutralizing Human Monoclonal Antibody MR191 Targets a Conserved Site to Block Virus Receptor Binding. <i>Cell Host and Microbe</i> , 2018, 23, 101-109.e4.	11.0	40
407	Non-natural amino acid peptide microarrays to discover Ebola virus glycoprotein ligands. <i>Chemical Communications</i> , 2018, 54, 1417-1420.	4.1	5
408	Novel cyclo-peptides inhibit Ebola pseudotyped virus entry by targeting primed GP protein. <i>Antiviral Research</i> , 2018, 155, 1-11.	4.1	18
409	Human transbodies that interfere with the functions of Ebola virus VP35 protein in genome replication and transcription and innate immune antagonism. <i>Emerging Microbes and Infections</i> , 2018, 7, 1-15.	6.5	32
410	Detection, characterization, and enrollment of donors of Ebola convalescent plasma in Sierra Leone. <i>Transfusion</i> , 2018, 58, 1289-1298.	1.6	23
411	Susceptibility of paramyxoviruses and filoviruses to inhibition by 2â€²-monofluoro- and 2â€²-difluoro-4â€²-azidocytidine analogs. <i>Antiviral Research</i> , 2018, 153, 101-113.	4.1	15
416	Improvement of the transient expression system for production of recombinant proteins in plants. <i>Scientific Reports</i> , 2018, 8, 4755.	3.3	129
417	Transmission, Human Population, and Pathogenicity: the Ebola Case in Point. <i>Microbiology Spectrum</i> , 2018, 6, .	3.0	6
418	Cloning and plantâ€‘based production of antibody <sc>MC</sc>10E7 for a lateral flow immunoassay to detect [4â€‘arginine]microcystin in freshwater. <i>Plant Biotechnology Journal</i> , 2018, 16, 27-38.	8.3	19
419	The transcriptome, extracellular proteome and active secretome of agroinfiltrated <i>Nicotiana benthamiana</i> uncover a large, diverse protease repertoire. <i>Plant Biotechnology Journal</i> , 2018, 16, 1068-1084.	8.3	54

#	ARTICLE	IF	CITATIONS
420	Beyond binding: antibody effector functions in infectious diseases. <i>Nature Reviews Immunology</i> , 2018, 18, 46-61.	22.7	516
421	Microfluidic single-cell technology in immunology and antibody screening. <i>Molecular Aspects of Medicine</i> , 2018, 59, 47-61.	6.4	66
422	Testing Experimental Therapies in a Guinea Pig Model for Hemorrhagic Fever. <i>Methods in Molecular Biology</i> , 2018, 1604, 269-278.	0.9	1
423	A synthetic biology approach for consistent production of plant-made recombinant polyclonal antibodies against snake venom toxins. <i>Plant Biotechnology Journal</i> , 2018, 16, 727-736.	8.3	30
424	N-glycan engineering of a plant-produced anti-CD20 chimeric immunocytokine significantly enhances its effector functions. <i>Biotechnology and Bioengineering</i> , 2018, 115, 565-576.	3.3	26
425	Gene Transfer of ZMapp Antibodies Mediated by Recombinant Adeno-Associated Virus Protects Against Ebola Infections. <i>Human Gene Therapy</i> , 2018, 29, 452-466.	2.7	13
426	Algae-Made Anti-Hepatitis B Antibody Binds to Human Fc γ 3 Receptors. <i>Biotechnology Journal</i> , 2018, 13, e1700496.	3.5	39
427	Treatment-focused Ebola trials, supportive care and future of filovirus care. <i>Expert Review of Anti-Infective Therapy</i> , 2018, 16, 67-76.	4.4	9
428	Ebola virus disease: an update on post-exposure prophylaxis. <i>Lancet Infectious Diseases</i> , The, 2018, 18, e183-e192.	9.1	112
429	From bench to almost bedside: the long road to a licensed Ebola virus vaccine. <i>Expert Opinion on Biological Therapy</i> , 2018, 18, 159-173.	3.1	35
430	Convergence Education of Medicine and Theology in a Secular Age. <i>Education Sciences</i> , 2018, 8, 201.	2.6	0
432	Bioinformatics Approach to Screening and Developing Drug against Ebola. , 0, , .		0
433	Ã%bola, abordaje clÃnico integral. <i>Revista Facultad De Medicina</i> , 2018, 66, 293-299.	0.2	0
434	A modified anthrax toxin-based enzyme-linked immunospot assay reveals robust T cell responses in symptomatic and asymptomatic Ebola virus exposed individuals. <i>PLoS Neglected Tropical Diseases</i> , 2018, 12, e0006530.	3.0	5
435	Investigation of Outbreak-Specific Nonsynonymous Mutations on Ebolavirus GP in the Context of Known Immune Reactivity. <i>Journal of Immunology Research</i> , 2018, 2018, 1-11.	2.2	0
436	Virus-Host Interactions: New Insights and Advances in Drug Development Against Viral Pathogens. <i>Current Drug Metabolism</i> , 2018, 18, 942-970.	1.2	8
437	Establishment of a Chinese street rabies virus library and its application for detecting neutralizing activity. <i>Infectious Diseases of Poverty</i> , 2018, 7, 117.	3.7	6
438	Efficacy of Human Monoclonal Antibody Monotherapy Against Bundibugyo Virus Infection in Nonhuman Primates. <i>Journal of Infectious Diseases</i> , 2018, 218, S565-S573.	4.0	13

#	ARTICLE	IF	CITATIONS
439	Identification of Diaryl-Quinoline Compounds as Entry Inhibitors of Ebola Virus. <i>Viruses</i> , 2018, 10, 678.	3.3	24
440	Persistence and Sexual Transmission of Filoviruses. <i>Viruses</i> , 2018, 10, 683.	3.3	62
441	Principles of Recombinant DNA Technology. <i>AAPS Introductions in the Pharmaceutical Sciences</i> , 2018, , 1-29.	0.1	0
442	A Novel Neutralizing Antibody Specific to the DE Loop of VP1 Can Inhibit EV-D68 Infection in Mice. <i>Journal of Immunology</i> , 2018, 201, 2557-2569.	0.8	16
443	Coformulation of Broadly Neutralizing Antibodies 3BNC117 and PGT121: Analytical Challenges During Preformulation Characterization and Storage Stability Studies. <i>Journal of Pharmaceutical Sciences</i> , 2018, 107, 3032-3046.	3.3	18
444	High-resolution epidemic simulation using within-host infection and contact data. <i>BMC Public Health</i> , 2018, 18, 886.	2.9	21
445	Development and Characterization of Neutralizing Antibodies Against Zaire Ebolavirus Glycoprotein and Protein 40. <i>Cellular Physiology and Biochemistry</i> , 2018, 50, 1055-1067.	1.6	5
446	Antibody-mediated protection against Ebola virus. <i>Nature Immunology</i> , 2018, 19, 1169-1178.	14.5	127
447	Phenotypic Prioritization of Diphyllin Derivatives That Block Filoviral Cell Entry by Vacuolar (H ⁺)-ATPase Inhibition. <i>ChemMedChem</i> , 2018, 13, 2664-2676.	3.2	14
448	Antiviral Agents Against Ebola Virus Infection: Repositioning Old Drugs and Finding Novel Small Molecules. <i>Annual Reports in Medicinal Chemistry</i> , 2018, 51, 135-173.	0.9	12
449	Structural Basis of Pan-Ebolavirus Neutralization by an Antibody Targeting the Glycoprotein Fusion Loop. <i>Cell Reports</i> , 2018, 24, 2723-2732.e4.	6.4	26
450	Intranasal vaccination with ebola virus GP amino acids 258-601 protects mice against lethal challenge. <i>Vaccine</i> , 2018, 36, 6053-6060.	3.8	8
451	An Effective Way of Producing Fully Assembled Antibody in Transgenic Tobacco Plants by Linking Heavy and Light Chains via a Self-Cleaving 2A Peptide. <i>Frontiers in Plant Science</i> , 2018, 9, 1379.	3.6	9
452	Transient Recombinant Protein Production in Glycoengineered <i>Nicotiana benthamiana</i> Cell Suspension Culture. <i>International Journal of Molecular Sciences</i> , 2018, 19, 1205.	4.1	32
453	Computational Models for Trapping Ebola Virus Using Engineered Bacteria. <i>IEEE/ACM Transactions on Computational Biology and Bioinformatics</i> , 2018, 15, 2017-2027.	3.0	8
454	Peek-Peak-Pique: Repeating Motifs of Subtle Variance Are Targets for Potent Malaria Antibodies. <i>Immunity</i> , 2018, 48, 851-854.	14.3	7
455	Vaccine-elicited receptor-binding site antibodies neutralize two New World hemorrhagic fever arenaviruses. <i>Nature Communications</i> , 2018, 9, 1884.	12.8	40
456	Engineering Plants for the Future: Farming with Value-Added Harvest. <i>Progress in Botany Fortschritte Der Botanik</i> , 2018, , 65-108.	0.3	7

#	ARTICLE	IF	CITATIONS
457	The structural basis for filovirus neutralization by monoclonal antibodies. <i>Current Opinion in Immunology</i> , 2018, 53, 196-202.	5.5	16
458	Broad Neutralizing Activity Against Ebolaviruses Lacking the Mucin-Like Domain in Convalescent Plasma Specimens From Patients With Ebola Virus Disease. <i>Journal of Infectious Diseases</i> , 2018, 218, S574-S581.	4.0	9
459	Efficacy of Ebola Glycoprotein-Specific Equine Polyclonal Antibody Product Against Lethal Ebola Virus Infection in Guinea Pigs. <i>Journal of Infectious Diseases</i> , 2018, 218, S603-S611.	4.0	6
460	Development of Clinical-Stage Human Monoclonal Antibodies That Treat Advanced Ebola Virus Disease in Nonhuman Primates. <i>Journal of Infectious Diseases</i> , 2018, 218, S612-S626.	4.0	146
461	Human Polyclonal Antibodies Produced by Transchromosomal Cattle Provide Partial Protection Against Lethal Zaire Ebolavirus Challenge in Rhesus Macaques. <i>Journal of Infectious Diseases</i> , 2018, 218, S658-S661.	4.0	10
462	The potential for immunoglobulins and host defense peptides (HDPs) to reduce the use of antibiotics in animal production. <i>Veterinary Research</i> , 2018, 49, 68.	3.0	26
463	Hydroponic Treatment of <i>Nicotiana benthamiana</i> with Kifunensine Modifies the N-glycans of Recombinant Glycoprotein Antigens to Predominantly Man9 High-Mannose Type upon Transient Overexpression. <i>Frontiers in Plant Science</i> , 2018, 9, 62.	3.6	18
464	Protein-Based Bioproducts. , 2018, , 143-175.		2
465	Ebola Immunity: Gaining a Winning Position in Lightning Chess. <i>Journal of Immunology</i> , 2018, 201, 833-842.	0.8	19
467	Qualitative Profiling of the Humoral Immune Response Elicited by rVSV- \hat{I}^{G} -EBOV-GP Using a Systems Serology Assay, Domain Programmable Arrays. <i>Cell Reports</i> , 2018, 24, 1050-1059.e5.	6.4	11
468	Rapid transient protein production by the coat protein-deficient cucumber mosaic virus vector: non-packaged CMV system, NoPaCS. <i>Plant Cell Reports</i> , 2018, 37, 1513-1522.	5.6	3
469	Development of Antibody Therapeutics against Flaviviruses. <i>International Journal of Molecular Sciences</i> , 2018, 19, 54.	4.1	51
470	Herpes simplex virus-binding IgG traps HSV in human cervicovaginal mucus across the menstrual cycle and diverse vaginal microbial composition. <i>Mucosal Immunology</i> , 2018, 11, 1477-1486.	6.0	29
471	Simple Purification of <i>Nicotiana benthamiana</i> -Produced Recombinant Colicins: High-Yield Recovery of Purified Proteins with Minimum Alkaloid Content Supports the Suitability of the Host for Manufacturing Food Additives. <i>International Journal of Molecular Sciences</i> , 2018, 19, 95.	4.1	22
472	Post-Exposure Protection in Mice against Sudan Virus by a Two Antibody Cocktail. <i>Viruses</i> , 2018, 10, 286.	3.3	16
473	Role of Antibodies in Protection Against Ebola Virus in Nonhuman Primates Immunized With Three Vaccine Platforms. <i>Journal of Infectious Diseases</i> , 2018, 218, S553-S564.	4.0	22
474	Vaccine Generation of Protective Ebola Antibodies and Identification of Conserved B-Cell Signatures. <i>Journal of Infectious Diseases</i> , 2018, 218, S528-S536.	4.0	17
475	Fully Human Immunoglobulin G From Transchromosomal Bovines Treats Nonhuman Primates Infected With Ebola Virus Makona Isolate. <i>Journal of Infectious Diseases</i> , 2018, 218, S636-S648.	4.0	19

#	ARTICLE	IF	CITATIONS
476	Multifunctional Pan-ebolavirus Antibody Recognizes a Site of Broad Vulnerability on the Ebolavirus Glycoprotein. <i>Immunity</i> , 2018, 49, 363-374.e10.	14.3	61
477	The Past Need Not Be Prologue: Recommendations for Testing and Positioning the Most-Promising Medical Countermeasures for the Next Outbreak of Ebola Virus Infection. <i>Journal of Infectious Diseases</i> , 2018, 218, S690-S697.	4.0	8
478	Growth-Adaptive Mutations in the Ebola Virus Makona Glycoprotein Alter Different Steps in the Virus Entry Pathway. <i>Journal of Virology</i> , 2018, 92, .	3.4	15
479	Advanced Plant-Based Glycan Engineering. <i>Frontiers in Bioengineering and Biotechnology</i> , 2018, 6, 81.	4.1	101
480	Broadly neutralizing antibodies from human survivors target a conserved site in the Ebola virus glycoprotein HR2â€™MPER region. <i>Nature Microbiology</i> , 2018, 3, 670-677.	13.3	68
481	Development of Locked Nucleic Acid Antisense Oligonucleotides Targeting Ebola Viral Proteins and Host Factor Niemann-Pick C1. <i>Nucleic Acid Therapeutics</i> , 2018, 28, 273-284.	3.6	17
482	Asymmetric antiviral effects of ebolavirus antibodies targeting glycoprotein stem and glycan cap. <i>PLoS Pathogens</i> , 2018, 14, e1007204.	4.7	16
483	Advances in Designing and Developing Vaccines, Drugs, and Therapies to Counter Ebola Virus. <i>Frontiers in Immunology</i> , 2018, 9, 1803.	4.8	65
484	Antibody-Dependent Enhancement of Ebola Virus Infection by Human Antibodies Isolated from Survivors. <i>Cell Reports</i> , 2018, 24, 1802-1815.e5.	6.4	64
485	A Role for Fc Function in Therapeutic Monoclonal Antibody-Mediated Protection against Ebola Virus. <i>Cell Host and Microbe</i> , 2018, 24, 221-233.e5.	11.0	182
486	A genome-wide siRNA screen identifies a druggable host pathway essential for the Ebola virus life cycle. <i>Genome Medicine</i> , 2018, 10, 58.	8.2	41
488	Systematic Analysis of Monoclonal Antibodies against Ebola Virus GP Defines Features that Contribute to Protection. <i>Cell</i> , 2018, 174, 938-952.e13.	28.9	173
489	Strength through Organization: Classifying Antibody Activity against EBOV. <i>Cell Host and Microbe</i> , 2018, 24, 185-186.	11.0	1
490	DNA-launched RNA replicon vaccines induce potent anti-Ebolavirus immune responses that can be further improved by a recombinant MVA boost. <i>Scientific Reports</i> , 2018, 8, 12459.	3.3	21
491	Tip Your Cap for Ebola Virus Neutralization. <i>Immunity</i> , 2018, 49, 204-206.	14.3	0
492	Broadly Reactive Human Monoclonal Antibodies Elicited following Pandemic H1N1 Influenza Virus Exposure Protect Mice against Highly Pathogenic H5N1 Challenge. <i>Journal of Virology</i> , 2018, 92, .	3.4	33
493	A novel Ebola virus antibody-dependent cell-mediated cytotoxicity (Ebola ADCC) assay. <i>Journal of Immunological Methods</i> , 2018, 460, 10-16.	1.4	8
494	Recombinant Therapeutic Molecules Produced in Plants. <i>Advances in Botanical Research</i> , 2018, 86, 207-244.	1.1	3

#	ARTICLE	IF	CITATIONS
495	Ebola Vaccines. , 2018, , 276-287.e5.		0
496	Inhibition of Ebola Virus by a Molecularly Engineered Banana Lectin. PLoS Neglected Tropical Diseases, 2019, 13, e0007595.	3.0	38
497	Production of Biopharmaceuticals in <i>Nicotiana benthamiana</i> —Axillary Stem Growth as a Key Determinant of Total Protein Yield. Frontiers in Plant Science, 2019, 10, 735.	3.6	23
498	Virus inoculation and treatment regimens for evaluating anti-filovirus monoclonal antibody efficacy in vivo. Biosafety and Health, 2019, 1, 6-13.	2.7	3
499	Therapeutic strategies to target the Ebola virus life cycle. Nature Reviews Microbiology, 2019, 17, 593-606.	28.6	110
500	Chimpanzee adenoviral vector prime-boost regimen elicits potent immune responses against Ebola virus in mice and rhesus macaques. Emerging Microbes and Infections, 2019, 8, 1086-1097.	6.5	13
501	Assessment of antiviral therapeutics in animal models of Lassa fever. Current Opinion in Virology, 2019, 37, 84-90.	5.4	4
502	Plant-Made Antibodies: Properties and Therapeutic Applications. Current Medicinal Chemistry, 2019, 26, 381-395.	2.4	12
503	Polyclonal and convergent antibody response to Ebola virus vaccine rVSV-ZEBOV. Nature Medicine, 2019, 25, 1589-1600.	30.7	92
504	Engineering a Novel Antibody-Peptide Bispecific Fusion Protein Against MERS-CoV. Antibodies, 2019, 8, 53.	2.5	8
505	The Roles of Ebola Virus Soluble Glycoprotein in Replication, Pathogenesis, and Countermeasure Development. Viruses, 2019, 11, 999.	3.3	29
506	Recent Advances in the Diagnosis and Management of Ebola Virus Disease. Clinical Microbiology Newsletter, 2019, 41, 185-189.	0.7	5
508	Repurposing Quinacrine against Ebola Virus Infection In Vivo. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	30
509	Understudied Factors Influencing Fc-Mediated Immune Responses against Viral Infections. Vaccines, 2019, 7, 103.	4.4	15
510	The NCATS Pharmaceutical Collection: a 10-year update. Drug Discovery Today, 2019, 24, 2341-2349.	6.4	48
511	Ebola Virus: Pathogenesis and Countermeasure Development. Annual Review of Virology, 2019, 6, 435-458.	6.7	50
512	Rekombinante Antikörper. , 2019, , .		1
513	Randomization tests in clinical trials. Statistics in Medicine, 2019, 38, 2292-2302.	1.6	22

#	ARTICLE	IF	CITATIONS
514	Current state-of-the-art in plant-based antibody production systems. <i>Biotechnology Letters</i> , 2019, 41, 335-346.	2.2	63
515	Safety, tolerability, pharmacokinetics, and immunogenicity of the therapeutic monoclonal antibody mAb114 targeting Ebola virus glycoprotein (VRC 608): an open-label phase 1 study. <i>Lancet, The</i> , 2019, 393, 889-898.	13.7	99
516	Plant Molecular Farming – Integration and Exploitation of Side Streams to Achieve Sustainable Biomanufacturing. <i>Frontiers in Plant Science</i> , 2018, 9, 1893.	3.6	94
517	Coupling multiscale within-host dynamics and between-host transmission with recovery (SIR) dynamics. <i>Mathematical Biosciences</i> , 2019, 309, 34-41.	1.9	14
518	Current and Novel Approaches in Influenza Management. <i>Vaccines</i> , 2019, 7, 53.	4.4	14
519	Posttranslational Modification of Heterologous Human Therapeutics in Plant Host Expression Systems. , 2019, , 145-169.		0
520	An Alternative Medical Diagnosis Method: Biosensors for Virus Detection. <i>Biosensors</i> , 2019, 9, 65.	4.7	201
521	Mechanism of Inhibition of Ebola Virus RNA-Dependent RNA Polymerase by Remdesivir. <i>Viruses</i> , 2019, 11, 326.	3.3	478
522	Current status of small molecule drug development for Ebola virus and other filoviruses. <i>Current Opinion in Virology</i> , 2019, 35, 42-56.	5.4	35
523	An overview of tolerogenic immunotherapies based on plant-made antigens. <i>Expert Opinion on Biological Therapy</i> , 2019, 19, 587-599.	3.1	0
524	Generation and Characterization of Anti-Filovirus Nucleoprotein Monoclonal Antibodies. <i>Viruses</i> , 2019, 11, 259.	3.3	5
525	Generating digital drug cocktails via optical manipulation of drug-containing particles and photo-patterning of hydrogels. <i>Lab on A Chip</i> , 2019, 19, 1764-1771.	6.0	10
526	Antibody responses to viral infections: a structural perspective across three different enveloped viruses. <i>Nature Microbiology</i> , 2019, 4, 734-747.	13.3	158
527	Achieving cross-reactivity with pan-ebolavirus antibodies. <i>Current Opinion in Virology</i> , 2019, 34, 140-148.	5.4	18
528	Design of a multiepitopic Zaire ebolavirus protein and its expression in plant cells. <i>Journal of Biotechnology</i> , 2019, 295, 41-48.	3.8	10
529	Structural basis of broad ebolavirus neutralization by a human survivor antibody. <i>Nature Structural and Molecular Biology</i> , 2019, 26, 204-212.	8.2	30
530	In Vitro Characterization and In Vivo Effectiveness of Ebola Virus Specific Equine Polyclonal F(ab ²). <i>Journal of Infectious Diseases</i> , 2019, 220, 41-45.	4.0	4
531	NK Cells Accumulate in Infected Tissues and Contribute to Pathogenicity of Ebola Virus in Mice. <i>Journal of Virology</i> , 2019, 93, .	3.4	13

#	ARTICLE	IF	CITATIONS
532	Maximum Containment Infectious Disease Laboratories as an Integral Part of Emergency Preparedness and Emergency Response. , 2019, , 125-144.		0
533	Towards a solution to MERS: protective human monoclonal antibodies targeting different domains and functions of the MERS-coronavirus spike glycoprotein. <i>Emerging Microbes and Infections</i> , 2019, 8, 516-530.	6.5	99
535	Therapeutic Monoclonal Antibodies for Ebola Virus Infection Derived from Vaccinated Humans. <i>Cell Reports</i> , 2019, 27, 172-186.e7.	6.4	69
536	Expanding the watch list for potential Ebola virus antibody escape mutations. <i>PLoS ONE</i> , 2019, 14, e0211093.	2.5	25
537	Early Human B Cell Response to Ebola Virus in Four U.S. Survivors of Infection. <i>Journal of Virology</i> , 2019, 93, .	3.4	15
538	Modeling Ebola Virus Infection. , 2019, , 85-103.		0
540	Transmission, Human Population, and Pathogenicity: the Ebola Case in Point. , 2019, , 263-278.		0
541	Ebola Virus Disease. <i>Infectious Disease Clinics of North America</i> , 2019, 33, 953-976.	5.1	36
542	Generation and Characterization of a Mouse-Adapted Makona Variant of Ebola Virus. <i>Viruses</i> , 2019, 11, 987.	3.3	13
543	A Randomized, Controlled Trial of Ebola Virus Disease Therapeutics. <i>New England Journal of Medicine</i> , 2019, 381, 2293-2303.	27.0	1,171
544	Characterization of Antigenic MHC-Class-I-Restricted T Cell Epitopes in the Glycoprotein of Ebolavirus. <i>Cell Reports</i> , 2019, 29, 2537-2545.e3.	6.4	7
545	Repurposing the antimalarial pyronaridine tetraphosphate to protect against Ebola virus infection. <i>PLoS Neglected Tropical Diseases</i> , 2019, 13, e0007890.	3.0	42
546	Expression of the Biologically Active Insulin Analog SCI-57 in <i>Nicotiana Benthamiana</i> . <i>Frontiers in Pharmacology</i> , 2019, 10, 1335.	3.5	7
547	An antibody against the F glycoprotein inhibits Nipah and Hendra virus infections. <i>Nature Structural and Molecular Biology</i> , 2019, 26, 980-987.	8.2	69
548	Structural Characterization of Pan-Ebolavirus Antibody 6D6 Targeting the Fusion Peptide of the Surface Glycoprotein. <i>Journal of Infectious Diseases</i> , 2019, 219, 415-419.	4.0	19
549	Can Ebola Virus Vaccines Have Universal Immune Correlates of protection?. <i>Trends in Microbiology</i> , 2019, 27, 8-16.	7.7	32
550	Equine-Origin Immunoglobulin Fragments Protect Nonhuman Primates from Ebola Virus Disease. <i>Journal of Virology</i> , 2019, 93, .	3.4	14
551	Measles-vectored vaccine approaches against viral infections: a focus on Chikungunya. <i>Expert Review of Vaccines</i> , 2019, 18, 393-403.	4.4	18

#	ARTICLE	IF	CITATIONS
552	A Recombinant Rabies Virus Expressing the Marburg Virus Glycoprotein Is Dependent upon Antibody-Mediated Cellular Cytotoxicity for Protection against Marburg Virus Disease in a Murine Model. <i>Journal of Virology</i> , 2019, 93, .	3.4	19
553	Perspectives towards antiviral drug discovery against Ebola virus. <i>Journal of Medical Virology</i> , 2019, 91, 2029-2048.	5.0	35
554	Development of a Human Antibody Cocktail that Deploys Multiple Functions to Confer Pan-Ebolavirus Protection. <i>Cell Host and Microbe</i> , 2019, 25, 39-48.e5.	11.0	83
555	A Two-Antibody Pan-Ebolavirus Cocktail Confers Broad Therapeutic Protection in Ferrets and Nonhuman Primates. <i>Cell Host and Microbe</i> , 2019, 25, 49-58.e5.	11.0	82
556	Post-exposure immunotherapy for two ebolaviruses and Marburg virus in nonhuman primates. <i>Nature Communications</i> , 2019, 10, 105.	12.8	45
557	Lab-on-a-chip techniques for high-throughput proteomics and drug discovery. , 2019, , 371-422.		4
558	Antibody-Mediated Protective Mechanisms Induced by a Trivalent Parainfluenza Virus-Vectored Ebolavirus Vaccine. <i>Journal of Virology</i> , 2019, 93, .	3.4	13
559	The Expanded Access Cure: A Twenty-First Century Framework for Companies. <i>Journal of Business Ethics</i> , 2019, 156, 155-171.	6.0	0
560	Ebola and Marburg Virus: A Brief Review. , 2020, , 201-218.		0
561	Randomized, Blinded, Dose-Ranging Trial of an Ebola Virus Glycoprotein Nanoparticle Vaccine With Matrix-M Adjuvant in Healthy Adults. <i>Journal of Infectious Diseases</i> , 2020, 222, 572-582.	4.0	38
562	An evolutionary insight into emerging Ebolavirus strains isolated in Africa. <i>Journal of Medical Virology</i> , 2020, 92, 988-995.	5.0	2
563	The induction and characterization of monoclonal antibodies specific to GP of Ebola virus. <i>Journal of Medical Virology</i> , 2020, 92, 996-1006.	5.0	1
564	Ebola Virus in the Democratic Republic of the Congo. <i>Chest</i> , 2020, 157, 42-46.	0.8	9
565	High Level Production of Monoclonal Antibodies Using an Optimized Plant Expression System. <i>Frontiers in Bioengineering and Biotechnology</i> , 2019, 7, 472.	4.1	72
567	Hemorrhagic Fevers. , 2020, , 119-138.		0
568	Ebola virus disease: An emerging and re-emerging viral threat. <i>Journal of Autoimmunity</i> , 2020, 106, 102375.	6.5	79
569	Towards quantification of protective antibody responses by passive transfer of the 1st WHO International Standard for Ebola virus antibody in a guinea pig model. <i>Vaccine</i> , 2020, 38, 345-349.	3.8	4
570	Immunological Perspective for Ebola Virus Infection and Various Treatment Measures Taken to Fight the Disease. <i>Pathogens</i> , 2020, 9, 850.	2.8	16

#	ARTICLE	IF	CITATIONS
571	To B or Not to B: Mechanisms of Protection Conferred by rVSV-EBOV-GP and the Roles of Innate and Adaptive Immunity. <i>Microorganisms</i> , 2020, 8, 1473.	3.6	12
572	Development of coumarine derivatives as potent anti-filovirus entry inhibitors targeting viral glycoprotein. <i>European Journal of Medicinal Chemistry</i> , 2020, 204, 112595.	5.5	10
573	The recent challenges of highly contagious COVID-19, causing respiratory infections: Symptoms, diagnosis, transmission, possible vaccines, animal models, and immunotherapy. <i>Chemical Biology and Drug Design</i> , 2020, 96, 1187-1208.	3.2	91
574	Plant Molecular Farming: A Viable Platform for Recombinant Biopharmaceutical Production. <i>Plants</i> , 2020, 9, 842.	3.5	133
575	COVID-19 vaccine development and a potential nanomaterial path forward. <i>Nature Nanotechnology</i> , 2020, 15, 646-655.	31.5	501
576	Pyronaridine tetrphosphate efficacy against Ebola virus infection in guinea pig. <i>Antiviral Research</i> , 2020, 181, 104863.	4.1	16
577	Quantum leap of monoclonal antibody (mAb) discovery and development in the COVID-19 era. <i>Seminars in Immunology</i> , 2020, 50, 101427.	5.6	31
578	The Emergency Response Capacity of Plant-Based Biopharmaceutical Manufacturing-What It Is and What It Could Be. <i>Frontiers in Plant Science</i> , 2020, 11, 594019.	3.6	48
579	Repurposing Pyramax®, quinacrine and tilorone as treatments for Ebola virus disease. <i>Antiviral Research</i> , 2020, 182, 104908.	4.1	20
580	Designs and Characterization of Subunit Ebola GP Vaccine Candidates: Implications for Immunogenicity. <i>Frontiers in Immunology</i> , 2020, 11, 586595.	4.8	8
581	Plant-based vaccines and antibodies to combat COVID-19: current status and prospects. <i>Human Vaccines and Immunotherapeutics</i> , 2020, 16, 2913-2920.	3.3	39
582	A Highly Expressing, Soluble, and Stable Plant-Made IgG Fusion Vaccine Strategy Enhances Antigen Immunogenicity in Mice Without Adjuvant. <i>Frontiers in Immunology</i> , 2020, 11, 576012.	4.8	9
583	Recent advances in therapeutic applications of neutralizing antibodies for virus infections: an overview. <i>Immunologic Research</i> , 2020, 68, 325-339.	2.9	39
584	AAV Vected Immunoprophylaxis for Filovirus Infections. <i>Tropical Medicine and Infectious Disease</i> , 2020, 5, 169.	2.3	11
585	Toward the Target: Tilorone, Quinacrine, and Pyronaridine Bind to Ebola Virus Glycoprotein. <i>ACS Medicinal Chemistry Letters</i> , 2020, 11, 1653-1658.	2.8	15
586	From Farm to Finger Prick—A Perspective on How Plants Can Help in the Fight Against COVID-19. <i>Frontiers in Bioengineering and Biotechnology</i> , 2020, 8, 782.	4.1	23
587	Prior vaccination with rVSV-ZEBOV does not interfere with but improves efficacy of postexposure antibody treatment. <i>Nature Communications</i> , 2020, 11, 3736.	12.8	11
588	Redesigning plant cell walls for the biomass-based bioeconomy. <i>Journal of Biological Chemistry</i> , 2020, 295, 15144-15157.	3.4	48

#	ARTICLE	IF	CITATIONS
589	The Antiviral, Anti-Inflammatory Effects of Natural Medicinal Herbs and Mushrooms and SARS-CoV-2 Infection. <i>Nutrients</i> , 2020, 12, 2573.	4.1	66
590	Plant science decadal vision 2020â€“2030: Reimagining the potential of plants for a healthy and sustainable future. <i>Plant Direct</i> , 2020, 4, e00252.	1.9	26
591	Recent successes in therapeutics for Ebola virus disease: no time for complacency. <i>Lancet Infectious Diseases</i> , The, 2020, 20, e231-e237.	9.1	42
592	The immunology of SARS-CoV-2 infection, the potential antibody based treatments and vaccination strategies. <i>Expert Review of Anti-Infective Therapy</i> , 2020, 19, 1-12.	4.4	10
593	Inducible expression of antigens in plants: a study focused on peptides related to multiple sclerosis immunotherapy. <i>Journal of Biotechnology</i> , 2020, 318, 51-56.	3.8	8
594	Discovery and Structural Optimization of 4-(Aminomethyl)benzamides as Potent Entry Inhibitors of Ebola and Marburg Virus Infections. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 7211-7225.	6.4	16
595	Filoviruses Use the HOPS Complex and UVRAG To Traffic to Niemann-Pick C1 Compartments during Viral Entry. <i>Journal of Virology</i> , 2020, 94, .	3.4	5
596	Neutralization of SARS-CoV-2 by Destruction of the Prefusion Spike. <i>Cell Host and Microbe</i> , 2020, 28, 445-454.e6.	11.0	298
597	Virus detection using nanosensors. , 2020, , 501-511.		26
598	Perspectives for Glyco-Engineering of Recombinant Biopharmaceuticals from Microalgae. <i>Cells</i> , 2020, 9, 633.	4.1	41
599	Potent neutralizing monoclonal antibodies against Ebola virus isolated from vaccinated donors. <i>MAbs</i> , 2020, 12, 1742457.	5.2	18
600	Prospects for the Production of Recombinant Therapeutic Proteins and Peptides in Plants: Special Focus on Angiotensin I-Converting Enzyme Inhibitory (ACEI) Peptides. , 0, , .		2
601	The potential of plant-made vaccines to fight picornavirus. <i>Expert Review of Vaccines</i> , 2020, 19, 599-610.	4.4	2
602	Ebola virus disease. <i>Nature Reviews Disease Primers</i> , 2020, 6, 13.	30.5	340
603	Structural Basis for a Convergent Immune Response against Ebola Virus. <i>Cell Host and Microbe</i> , 2020, 27, 418-427.e4.	11.0	25
604	A Bivalent, Spherical Virus-Like Particle Vaccine Enhances Breadth of Immune Responses against Pathogenic Ebola Viruses in Rhesus Macaques. <i>Journal of Virology</i> , 2020, 94, .	3.4	17
605	Sialoglycans and genetically engineered plants. , 2020, , 63-85.		0
606	Molecular farming â€“ The slope of enlightenment. <i>Biotechnology Advances</i> , 2020, 40, 107519.	11.7	116

#	ARTICLE	IF	CITATIONS
607	A Chimeric Sudan Virus-Like Particle Vaccine Candidate Produced by a Recombinant Baculovirus System Induces Specific Immune Responses in Mice and Horses. <i>Viruses</i> , 2020, 12, 64.	3.3	6
608	Biomimetic Design of Peptide Neutralizer of Ebola Virus with Molecular Simulation. <i>Langmuir</i> , 2020, 36, 1813-1821.	3.5	16
609	Characterization of Ebola Virus Disease (EVD) in Rhesus Monkeys for Development of EVD Therapeutics. <i>Viruses</i> , 2020, 12, 92.	3.3	16
610	Development of an antibody cocktail for treatment of Sudan virus infection. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 3768-3778.	7.1	23
611	Potential Applications of Plant Biotechnology against SARS-CoV-2. <i>Trends in Plant Science</i> , 2020, 25, 635-643.	8.8	135
612	Tolcapone Potently Inhibits Seminal Amyloid Fibrils Formation and Blocks Entry of Ebola Pseudoviruses. <i>Frontiers in Microbiology</i> , 2020, 11, 504.	3.5	3
613	Neutralizing Monoclonal Antibodies against the Gn and the Gc of the Andes Virus Glycoprotein Spike Complex Protect from Virus Challenge in a Preclinical Hamster Model. <i>MBio</i> , 2020, 11, .	4.1	31
614	Hydrophobin-Protein A Fusion Protein Produced in Plants Efficiently Purified an Anti-West Nile Virus Monoclonal Antibody from Plant Extracts via Aqueous Two-Phase Separation. <i>International Journal of Molecular Sciences</i> , 2020, 21, 2140.	4.1	18
615	High-Yield Production of the Major Birch Pollen Allergen Bet v 1 With Allergen Immunogenicity in <i>Nicotiana benthamiana</i> . <i>Frontiers in Plant Science</i> , 2020, 11, 344.	3.6	13
616	Ethics of Conducting Clinical Research in an Outbreak Setting. <i>Annual Review of Virology</i> , 2020, 7, 475-494.	6.7	10
618	An Immunodominant Epitope-Specific Monoclonal Antibody Cocktail Improves Survival in a Mouse Model of <i>Staphylococcus aureus</i> Bacteremia. <i>Journal of Infectious Diseases</i> , 2021, 223, 1743-1752.	4.0	7
619	Antiviral therapies: advances and perspectives. <i>Fundamental and Clinical Pharmacology</i> , 2021, 35, 305-320.	1.9	30
620	Identification of two subtilisin-like serine proteases engaged in the degradation of recombinant proteins in <i>Nicotiana benthamiana</i> . <i>FEBS Letters</i> , 2021, 595, 379-388.	2.8	12
621	A combined pH and temperature precipitation step facilitates the purification of tobacco-derived recombinant proteins that are sensitive to extremes of either parameter. <i>Biotechnology Journal</i> , 2021, 16, e2000340.	3.5	10
622	Review of Ebola virus disease in children – how far have we come?. <i>Paediatrics and International Child Health</i> , 2021, 41, 12-27.	1.0	5
623	Antibody-Dependent Natural Killer Cell Activation After Ebola Vaccination. <i>Journal of Infectious Diseases</i> , 2021, 223, 1171-1182.	4.0	22
624	Hybridoma technology: is it still useful?. <i>Current Research in Immunology</i> , 2021, 2, 32-40.	2.8	17
625	Atypical Ebola Virus Disease in a Nonhuman Primate following Monoclonal Antibody Treatment Is Associated with Glycoprotein Mutations within the Fusion Loop. <i>MBio</i> , 2021, 12, .	4.1	10

#	ARTICLE	IF	CITATIONS
626	Analysis of an Ebola virus disease survivor whose host and viral markers were predictive of death indicates the effectiveness of medical countermeasures and supportive care. <i>Genome Medicine</i> , 2021, 13, 5.	8.2	9
627	An immunotoxin targeting Ebola virus glycoprotein inhibits Ebola virus production from infected cells. <i>PLoS ONE</i> , 2021, 16, e0245024.	2.5	4
628	Use of Immunoglobulins in the Prevention of Viral Infections. , 2021, , 267-280.		1
629	Alpha-1 antitrypsin deficiency and recombinant protein sources with focus on plant sources: Updates, challenges and perspectives. <i>Free Radical Biology and Medicine</i> , 2021, 163, 10-30.	2.9	8
630	COVID-19 Crisis: How Can Plant Biotechnology Help?. <i>Plants</i> , 2021, 10, 352.	3.5	12
631	Characterization of Ebola Virus Risk to Bedside Providers in an Intensive Care Environment. <i>Microorganisms</i> , 2021, 9, 498.	3.6	1
632	Evidence for distinct mechanisms of small molecule inhibitors of filovirus entry. <i>PLoS Pathogens</i> , 2021, 17, e1009312.	4.7	16
633	Importance of Genetic Engineering and Gene Therapy in the Management of Viral Diseases and Outbreaks. <i>Journal of Evolution of Medical and Dental Sciences</i> , 2021, 10, 357-361.	0.1	0
634	Efficient base editing in tomato using a highly expressed transient system. <i>Plant Cell Reports</i> , 2021, 40, 667-676.	5.6	8
635	Prominent Neutralizing Antibody Response Targeting the Ebolavirus Glycoprotein Subunit Interface Elicited by Immunization. <i>Journal of Virology</i> , 2021, 95, .	3.4	6
636	Immunotherapeutic strategies to target vulnerabilities in the Ebolavirus glycoprotein. <i>Immunity</i> , 2021, 54, 412-436.	14.3	23
637	Early control of viral load by favipiravir promotes survival to Ebola virus challenge and prevents cytokine storm in non-human primates. <i>PLoS Neglected Tropical Diseases</i> , 2021, 15, e0009300.	3.0	6
638	Pathogen Dose in Animal Models of Hemorrhagic Fever Virus Infections and the Potential Impact on Studies of the Immune Response. <i>Pathogens</i> , 2021, 10, 275.	2.8	3
639	Singleâ€Cell Microgels for Diagnostics and Therapeutics. <i>Advanced Functional Materials</i> , 2021, 31, 2009946.	14.9	14
640	Targeting Ebola virus replication through pharmaceutical intervention. <i>Expert Opinion on Investigational Drugs</i> , 2021, 30, 201-226.	4.1	11
641	Immunotherapeutics for Ebola Virus Disease: Hope on the Horizon. <i>Biologics: Targets and Therapy</i> , 2021, Volume 15, 79-86.	3.2	9
642	Prolyl Hydroxylase Paralogs in <i>Nicotiana benthamiana</i> Show High Similarity With Regard to Substrate Specificity. <i>Frontiers in Plant Science</i> , 2021, 12, 636597.	3.6	10
643	Structure-based development of three- and four-antibody cocktails against SARS-CoV-2 via multiple mechanisms. <i>Cell Research</i> , 2021, 31, 597-600.	12.0	26

#	ARTICLE	IF	CITATIONS
644	IgY antibodies against Ebola virus possess post-exposure protection in a murine pseudovirus challenge model and excellent thermostability. <i>PLoS Neglected Tropical Diseases</i> , 2021, 15, e0008403.	3.0	19
645	A Fc engineering approach to define functional humoral correlates of immunity against Ebola virus. <i>Immunity</i> , 2021, 54, 815-828.e5.	14.3	34
646	Convergence of a common solution for broad ebolavirus neutralization by glycan cap-directed human antibodies. <i>Cell Reports</i> , 2021, 35, 108984.	6.4	22
647	Development of a New Reverse Genetics System for Ebola Virus. <i>MSphere</i> , 2021, 6, .	2.9	8
649	Engineered Human Monoclonal scFv to Receptor Binding Domain of Ebolavirus. <i>Vaccines</i> , 2021, 9, 457.	4.4	5
650	Single-component multilayered self-assembling nanoparticles presenting rationally designed glycoprotein trimers as Ebola virus vaccines. <i>Nature Communications</i> , 2021, 12, 2633.	12.8	25
651	Application of 3D bioprinting in the prevention and the therapy for human diseases. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 177.	17.1	55
652	Antibody responses to filovirus infections in humans: protective or not?. <i>Lancet Infectious Diseases</i> , The, 2021, 21, e348-e355.	9.1	3
653	Crimean-Congo Hemorrhagic Fever Virus: Current Advances and Future Prospects of Antiviral Strategies. <i>Viruses</i> , 2021, 13, 1195.	3.3	19
654	Specialized Metabolites and Valuable Molecules in Crop and Medicinal Plants: The Evolution of Their Use and Strategies for Their Production. <i>Genes</i> , 2021, 12, 936.	2.4	20
655	Hepatitis C virus E2 envelope glycoprotein produced in <i>Nicotiana benthamiana</i> triggers humoral response with virus-neutralizing activity in vaccinated mice. <i>Plant Biotechnology Journal</i> , 2021, 19, 2027-2039.	8.3	8
657	Role of plasmonics in detection of deadliest viruses: a review. <i>European Physical Journal Plus</i> , 2021, 136, 675.	2.6	7
658	Screening of potent neutralizing antibodies against SARS-CoV-2 using convalescent patients-derived phage-display libraries. <i>Cell Discovery</i> , 2021, 7, 57.	6.7	28
659	Proteo-Genomic Analysis Identifies Two Major Sites of Vulnerability on Ebolavirus Glycoprotein for Neutralizing Antibodies in Convalescent Human Plasma. <i>Frontiers in Immunology</i> , 2021, 12, 706757.	4.8	4
660	Combating Human Viral Diseases: Will Plant-Based Vaccines Be the Answer?. <i>Vaccines</i> , 2021, 9, 761.	4.4	17
661	The Rise of SARS-CoV-2 Variants and the Role of Convalescent Plasma Therapy for Management of Infections. <i>Life</i> , 2021, 11, 734.	2.4	34
662	Platforms for Production of Protein-Based Vaccines: From Classical to Next-Generation Strategies. <i>Biomolecules</i> , 2021, 11, 1072.	4.0	53
663	Intranasal Administration of a Monoclonal Neutralizing Antibody Protects Mice against SARS-CoV-2 Infection. <i>Viruses</i> , 2021, 13, 1498.	3.3	33

#	ARTICLE	IF	CITATIONS
664	Contributions of the international plant science community to the fight against human infectious diseases – part 1: epidemic and pandemic diseases. <i>Plant Biotechnology Journal</i> , 2021, 19, 1901-1920.	8.3	44
665	Establishment of a piscine myocarditis virus (PMCV) challenge model and testing of a plant-produced subunit vaccine candidate against cardiomyopathy syndrome (CMS) in Atlantic salmon <i>Salmo salar</i> . <i>Aquaculture</i> , 2021, 541, 736806.	3.5	8
666	Model-Informed Repurposing of Medicines for SARS-CoV-2: Extrapolation of Antiviral Activity and Dose Rationale for Paediatric Patients. <i>Pharmaceutics</i> , 2021, 13, 1299.	4.5	3
667	Plant Platforms for Efficient Heterologous Protein Production. <i>Biotechnology and Bioprocess Engineering</i> , 2021, 26, 546-567.	2.6	19
668	The Methanolic Extract of <i>Perilla frutescens</i> Robustly Restricts Ebola Virus Glycoprotein-Mediated Entry. <i>Viruses</i> , 2021, 13, 1793.	3.3	6
669	Remdesivir is efficacious in rhesus monkeys exposed to aerosolized Ebola virus. <i>Scientific Reports</i> , 2021, 11, 19458.	3.3	9
670	Medicinal Plants: Guests and Hosts in the Heterologous Expression of High-Value Products. <i>Planta Medica</i> , 2022, 88, 1175-1189.	1.3	1
671	The challenges with developing therapeutic monoclonal antibodies for pandemic application. <i>Expert Opinion on Drug Discovery</i> , 2022, 17, 5-8.	5.0	2
672	Plant-based vaccine research development against viral diseases with emphasis on Ebola virus disease: A review study. <i>Current Opinion in Pharmacology</i> , 2021, 60, 261-267.	3.5	6
673	Comparative whole-genome and proteomics analyses of the next seed bank and the original master seed bank of MucoRice-CTB 51A line, a rice-based oral cholera vaccine. <i>BMC Genomics</i> , 2021, 22, 59.	2.8	3
674	Isolation and light chain shuffling of a <i>Plasmodium falciparum</i> AMA1-specific human monoclonal antibody with growth inhibitory activity. <i>Malaria Journal</i> , 2021, 20, 37.	2.3	4
675	Correlation of Influenza B Haemagglutination Inhibitor, Single-Radial Haemolysis and Pseudotype-Based Microneutralisation Assays for Immunogenicity Testing of Seasonal Vaccines. <i>Vaccines</i> , 2021, 9, 100.	4.4	8
676	Development and application of therapeutic antibodies against COVID-19. <i>International Journal of Biological Sciences</i> , 2021, 17, 1486-1496.	6.4	47
677	Evaluation of Medical Countermeasures Against Ebolaviruses in Nonhuman Primate Models. <i>Methods in Molecular Biology</i> , 2017, 1628, 293-307.	0.9	3
678	COVID-19: Antiviral Agents, Antibody Development and Traditional Chinese Medicine. <i>Virologica Sinica</i> , 2020, 35, 685-698.	3.0	18
679	Nonhuman primate to human immunobridging to infer the protective effect of an Ebola virus vaccine candidate. <i>Npj Vaccines</i> , 2020, 5, 112.	6.0	45
680	A Cross-Reactive Humanized Monoclonal Antibody Targeting Fusion Glycoprotein Function Protects Ferrets Against Lethal Nipah Virus and Hendra Virus Infection. <i>Journal of Infectious Diseases</i> , 2020, 221, S471-S479.	4.0	39
681	How myeloid cells contribute to the pathogenesis of prominent emerging zoonotic diseases. <i>Journal of General Virology</i> , 2018, 99, 953-969.	2.9	13

#	ARTICLE	IF	CITATIONS
688	West Africa 2013: Re-examining Ebola. , 0, , 1-37.		1
689	Characterizing alpha helical properties of Ebola viral proteins as potential targets for inhibition of alpha-helix mediated protein-protein interactions. F1000Research, 2014, 3, 251.	1.6	9
690	Correlating the ability of VP24 protein from Ebola and Marburg viruses to bind human karyopherin to their immune suppression mechanism and pathogenicity using computational methods. F1000Research, 0, 3, 265.	1.6	8
691	Correlating the ability of VP24 protein from Ebola and Marburg viruses to bind human karyopherin to their immune suppression mechanism and pathogenicity using computational methods. F1000Research, 0, 3, 265.	1.6	3
692	Antiviral therapies against Ebola and other emerging viral diseases using existing medicines that block virus entry. F1000Research, 2015, 4, 30.	1.6	57
693	Antiviral therapies against Ebola and other emerging viral diseases using existing medicines that block virus entry. F1000Research, 2015, 4, 30.	1.6	63
694	Tobacco plant: A possible key to Ebola vaccine. Journal of Coastal Life Medicine, 2017, 5, 206-211.	0.2	4
695	The UCSC Ebola Genome Portal. PLOS Currents, 2014, 6, .	1.4	6
696	Conservancy of mAb Epitopes in Ebolavirus Glycoproteins of Previous and 2014 Outbreaks. PLOS Currents, 2014, 6, .	1.4	14
697	Systems Biology-Based Investigation of Cellular Antiviral Drug Targets Identified by Gene-Trap Insertional Mutagenesis. PLoS Computational Biology, 2016, 12, e1005074.	3.2	52
698	Antiviral efficacy of favipiravir against Ebola virus: A translational study in cynomolgus macaques. PLoS Medicine, 2018, 15, e1002535.	8.4	108
699	A Rapid Screening Assay Identifies Monotherapy with Interferon- α and Combination Therapies with Nucleoside Analogs as Effective Inhibitors of Ebola Virus. PLoS Neglected Tropical Diseases, 2016, 10, e0004364.	3.0	48
700	A human inferred germline antibody binds to an immunodominant epitope and neutralizes Zika virus. PLoS Neglected Tropical Diseases, 2017, 11, e0005655.	3.0	23
701	Development of an antigen detection assay for early point-of-care diagnosis of Zaire ebolavirus. PLoS Neglected Tropical Diseases, 2020, 14, e0008817.	3.0	8
702	Antibody Derived Peptides for Detection of Ebola Virus Glycoprotein. PLoS ONE, 2015, 10, e0135859.	2.5	15
703	Human Polyclonal Antibodies Produced through DNA Vaccination of Transchromosomal Cattle Provide Mice with Post-Exposure Protection against Lethal Zaire and Sudan Ebolaviruses. PLoS ONE, 2015, 10, e0137786.	2.5	24
704	New Perspectives on Ebola Virus Evolution. PLoS ONE, 2016, 11, e0160410.	2.5	6
705	Reverse epitope mapping of the E2 glycoprotein in antibody associated hepatitis C virus. PLoS ONE, 2017, 12, e0175349.	2.5	5

#	ARTICLE	IF	CITATIONS
706	Plant-expressed pyocins for control of <i>Pseudomonas aeruginosa</i> . PLoS ONE, 2017, 12, e0185782.	2.5	36
707	A prophylactic multivalent vaccine against different filovirus species is immunogenic and provides protection from lethal infections with Ebolavirus and Marburgvirus species in non-human primates. PLoS ONE, 2018, 13, e0192312.	2.5	64
708	Ebolavirus Evolution: Past and Present. PLoS Pathogens, 2015, 11, e1005221.	4.7	58
709	The Myeloid LSECtin Is a DAP12-Coupled Receptor That Is Crucial for Inflammatory Response Induced by Ebola Virus Glycoprotein. PLoS Pathogens, 2016, 12, e1005487.	4.7	28
710	Laboratory response checklist for infectious disease outbreaks—preparedness and response considerations for emerging threats. Canada Communicable Disease Report, 2020, 46, 311-321.	1.3	6
711	BioÉtica e investigaci3n: anÁlisis de caso de la epidemia por el virus del Ébola en 2014. Revista Latinoamericana De BioÉtica, 2016, 17, 124-149.	0.3	1
712	Ethics and Ebola: Public Health Planning and Response. SSRN Electronic Journal, 0, , .	0.4	23
713	Transient Production of Recombinant Pharmaceutical Proteins in Plants: Evolution and Perspectives. Current Medicinal Chemistry, 2019, 26, 365-380.	2.4	41
714	Antibody Therapy for the Control of Viral Diseases: An Update. Current Pharmaceutical Biotechnology, 2019, 20, 1108-1121.	1.6	27
715	Insights into Ebola Virus VP35 and VP24 Interferon Inhibitory Functions and their Initial Exploitation as Drug Targets. Infectious Disorders - Drug Targets, 2019, 19, 362-374.	0.8	17
716	Viruses Causing Hemorrhagic Fever. Safety Laboratory Procedures. The Open Virology Journal, 2016, 10, 1-9.	1.8	7
717	Recombinant Antibodies to the Ebola Virus Glycoprotein. Acta Naturae, 2017, 9, 84-91.	1.7	3
718	Ebola virus disease: Essential clinical knowledge. Avicenna Journal of Medicine, 2017, 07, 96-102.	0.8	12
719	Curcumin and natural derivatives inhibit Ebola viral proteins: An In silico approach. Pharmacognosy Research (discontinued), 2017, 9, 15.	0.6	22
720	Past, Present and Future about Ebola Virus Diseases: An Updated Review. Journal of Pharmacy Practice and Community Medicine, 2016, 2, 35-39.	0.1	2
721	Initiating a watch list for Ebola virus antibody escape mutations. PeerJ, 2016, 4, e1674.	2.0	36
722	Promising Therapeutics against Ebola Virus Disease. International Journal of Tropical Disease & Health, 2015, 10, 1-17.	0.1	1
723	Die Rolle Nationaler EthikrÁte in Pandemien. Orientierung in Krisenzeiten. , 2021, , 305-327.		0

#	ARTICLE	IF	CITATIONS
724	Immunoglobulin A Glycosylation and Its Role in Disease. <i>Experientia Supplementum</i> (2012), 2021, 112, 433-477.	0.9	7
725	The Interaction of Ebola Virus with the Immune System <i>Ebola and Immunity</i> . , 2021, , .		0
726	Modulating Neurological Complications of Emerging Infectious Diseases: Mechanistic Approaches to Candidate Phytochemicals. <i>Frontiers in Pharmacology</i> , 2021, 12, 742146.	3.5	1
727	Building a better antibody through the Fc: advances and challenges in harnessing antibody Fc effector functions for antiviral protection. <i>Human Vaccines and Immunotherapeutics</i> , 2021, 17, 4328-4344.	3.3	13
728	Identification and Characterization of a Novel Single Domain Antibody Against Ebola Virus. <i>Virologica Sinica</i> , 2021, 36, 1600-1610.	3.0	5
729	The Social Efficiency of Fairness. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
730	Compassionate Use of Candidate Drugs in Pre-Clinical Trial Phase for Ebola Hemorrhagic Fever . <i>Japanese Journal of Clinical Pharmacology and Therapeutics</i> , 2014, 45, 263-267.	0.1	0
731	Plantipharma Technology: Production of Antibodies, Anti-HIV, Anti-Ebola Virus, Anti-End-Stage Metastatic Melanoma and Other Recombinant Biotech Drugs in Crops. <i>Advances in Crop Science and Technology</i> , 2014, 02, .	0.4	1
732	Ebola drug saves infected monkeys. <i>Nature</i> , 0, , .	27.8	1
734	The 2014 Ebola Virus Outbreak in West Africa: Current Perspectives for Prevention and Treatment. <i>Journal of Human Virology & Retrovirology</i> , 2014, 1, .	0.2	4
735	Descriptive Analysis of Ebola virus Proteins: Towards Development of Effective Therapeutics and Vaccines. <i>British Microbiology Research Journal</i> , 2015, 8, 457-479.	0.2	1
736	Characterizing alpha helical properties of Ebola viral proteins as potential targets for inhibition of alpha-helix mediated protein-protein interactions. <i>F1000Research</i> , 2014, 3, 251.	1.6	7
737	Ebola Virus Disease. , 2015, , 543-559.		1
738	Ebola virus disease: a literature review. <i>Journal of Coastal Life Medicine</i> , 2015, , .	0.2	3
739	Druggableness of the Ebola Associated Genes in the Human Genome: Chemoinformatics Approaches. <i>MOJ Proteomics & Bioinformatics</i> , 2015, 2, .	0.1	1
740	Ebola Virus Disease: Emerging Outbreak. <i>International Journal of Medical and Dental Sciences</i> , 2015, 4, 946.	0.1	0
742	Ebola Fever and Advances in the Antiviral Therapies. <i>Journal of Human Virology & Retrovirology</i> , 2015, 2, .	0.2	0
743	Study on Laboratory Diagnosis of the Ebola Virus and Its Current Trends. <i>Korean Journal of Clinical Laboratory Science</i> , 2015, 47, 105-111.	0.3	0

#	ARTICLE	IF	CITATIONS
744	Ebola virus disease with special reference to epidemiology and management. <i>Veterinary Science Research Journal</i> , 2015, 6, 103-112.	0.0	0
745	<i>Filoviruses.</i> , 0, , 981-1007.		1
746	Preparing for Serious Communicable Diseases in the United States: What the Ebola Virus Epidemic Has Taught Us. , 0, , 39-52.		0
747	Ebola Virus Disease: Therapeutic and Potential Preventative Opportunities. , 0, , 53-71.		1
748	AVANCES CIENTÍFICOS EN LAS ESTRATEGIAS TERAPÉUTICAS CONTRA LA ENFERMEDAD POR VIRUS DEL ÉBOLA. <i>Biosalud</i> , 2016, 15, 87-105.	0.1	0
750	Chapter 17 Plant-Based Production of Biosimilar Drug Products. <i>Drugs and the Pharmaceutical Sciences</i> , 2017, , 439-458.	0.1	0
751	Humoral immune system targets clonotypic antibody-associated hepatitis C virus. <i>Journal of General Virology</i> , 2017, 98, 179-189.	2.9	1
753	Assessment of listing and categorisation of animal diseases within the framework of the Animal Health Law (Regulation (EU) No 2016/429): Ebola virus disease. <i>EFSA Journal</i> , 2017, 15, e04890.	1.8	1
755	Ebola Hemorrhagic Fever: Recent Update On Disease Status, Current Therapies And Advances In Treatment. <i>Journal of Pharmaceutical Technology Research and Management</i> , 2017, 5, 217-234.	0.2	1
756	Escalation (May 23, 2014â€“August 31, 2014). , 2018, , 23-79.		0
757	Therapeutic Monoclonal Antibodies for Ebola Virus Infection Derived from Vaccinated Humans. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
760	New insight of medical and molecular farming (MMF): the plants derived drugs. <i>MOJ Anatomy & Physiology</i> , 2018, 5, .	0.2	0
762	RECOMBINANT ANTIBODIES IN ANTI-VIRAL THERAPY: ACHIEVEMENTS AND PERSPECTIVES. <i>Zhurnal Mikrobiologii i Epidemiologii I Immunobiologii</i> , 2018, , 114-123.	1.0	0
764	Ebola Virus Disease - clinical manifestations, management and future therapies. <i>Journal of the Royal Naval Medical Service</i> , 2019, 105, 113-120.	0.0	0
766	Plant Platform for Therapeutic Monoclonal Antibody Production. , 2019, , 543-581.		0
767	Swords to Ploughshares and Back: The Continuing Threat of Immunomodulatory Research and Development. , 2019, , 195-223.		0
768	Immunoinformatics Approach Identified Two Highly Conserved B and T Cell Epitopes, LEASKRWAF and DSPLEASKRWAFRTG, for Effective Vaccine Design against Ebola and Marburg Viruses. <i>Journal of Advances in Microbiology</i> , 0, , 1-16.	0.2	0
772	Pan-ebolavirus protective therapy by two multifunctional human antibodies. <i>Cell</i> , 2021, 184, 5593-5607.e18.	28.9	21

#	ARTICLE	IF	CITATIONS
773	Transient expression of recombinant proteins in plants. <i>Methods in Enzymology</i> , 2021, 660, 193-203.	1.0	8
776	Therapeutic vaccination strategies against EBOV by rVSV-EBOV-GP: the role of innate immunity. <i>Current Opinion in Virology</i> , 2021, 51, 179-189.	5.4	7
778	A Method for Parameters Estimation in a Dynamical Model of Ebola Virus Transmission in Sierra Leone. <i>Complexity</i> , 2020, 2020, 1-9.	1.6	1
779	Antibody DDS therapeutics against cancer, inflammatory autoimmune and infectious disease. <i>Drug Delivery System</i> , 2020, 35, 356-366.	0.0	0
781	Updates on Treatment of Ebola Virus Disease. <i>The Malaysian Journal of Medical Sciences</i> , 2015, 22, 54-57.	0.5	0
782	Animal Models of Ebolavirus Infection. <i>Comparative Medicine</i> , 2017, 67, 253-262.	1.0	33
783	Recombinant Antibodies to the Ebola Virus Glycoprotein. <i>Acta Naturae</i> , 2017, 9, 84-91.	1.7	2
784	SARS-CoV-2 vaccines: current trends and prospects of developing plant-derived vaccines. , 2022, , 213-229.		5
786	Receptors on Primary Phagocytes as Therapeutic Targets Against Highly Pathogenic Emerging Viruses. <i>RSC Drug Discovery Series</i> , 2021, , 256-279.	0.3	0
787	Antiviral Strategies for Ebola Virus and Other Filoviruses: Antibodies. <i>RSC Drug Discovery Series</i> , 2021, , 91-120.	0.3	0
788	Glycosylation of Plant-Produced Immunoglobulins. <i>Experientia Supplementum (2012)</i> , 2021, 112, 519-543.	0.9	1
789	Reproducibility and flexibility of monoclonal antibody production with <i>Nicotiana benthamiana</i> . <i>MABs</i> , 2022, 14, 2013594.	5.2	7
790	Development of plant-made monoclonal antibodies against viral infections. <i>Current Opinion in Virology</i> , 2022, 52, 148-160.	5.4	19
791	Novel frontiers on ebola virus disease management: An update. <i>IP International Journal of Comprehensive and Advanced Pharmacology</i> , 2020, 5, 130-137.	0.3	0
792	Convalescent plasma therapy against the emerging SARS-CoV-2 variants: Delineation of the potentialities and risks. <i>International Journal of Surgery</i> , 2022, 97, 106204.	2.7	17
793	Nanosensors for virus detection. , 2022, , 531-546.		1
794	Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in children and adolescents in Africa: A randomised, placebo-controlled, multicentre Phase II clinical trial. <i>PLoS Medicine</i> , 2022, 19, e1003865.	8.4	27
795	Structural Biology Illuminates Molecular Determinants of Broad Ebolavirus Neutralization by Human Antibodies for Pan-Ebolavirus Therapeutic Development. <i>Frontiers in Immunology</i> , 2021, 12, 808047.	4.8	4

#	ARTICLE	IF	CITATIONS
796	Human Antibodies for Viral Infections. Annual Review of Immunology, 2022, 40, 349-386.	21.8	23
797	Ebola virus persistence and disease recrudescence in the brains of antibody-treated nonhuman primate survivors. Science Translational Medicine, 2022, 14, eabi5229.	12.4	22
799	Nanostructures for the Prevention, Diagnosis, and Treatment of SARS-CoV-2: A Review. ACS Applied Nano Materials, 2022, 5, 6029-6054.	5.0	12
800	Therapeutic Strategies against Ebola Virus Infection. Viruses, 2022, 14, 579.	3.3	16
801	Development and Structural Analysis of Antibody Therapeutics for Filoviruses. Pathogens, 2022, 11, 374.	2.8	7
802	Vaccine-Associated Enhanced Disease and Pathogenic Human Coronaviruses. Frontiers in Immunology, 2022, 13, 882972.	4.8	32
803	The road to effective and accessible antibody therapies against Ebola virus. Current Opinion in Virology, 2022, 54, 101210.	5.4	7
804	The discovery and development of novel treatment strategies for filoviruses. Expert Opinion on Drug Discovery, 2022, 17, 139-149.	5.0	9
805	Ebola Virus Entry Inhibitors. Advances in Experimental Medicine and Biology, 2022, 1366, 155-170.	1.6	3
806	Transient Expression of Glycosylated SARS-CoV-2 Antigens in Nicotiana benthamiana. Plants, 2022, 11, 1093.	3.5	12
807	CRISPR/Cas9-mediated knockout of a prolyl-4-hydroxylase subfamily in <i>Nicotiana benthamiana</i> using DsRed2 for plant selection. Biotechnology Journal, 2022, 17, e2100698.	3.5	9
817	Ebola virus disease outbreak: what's going on. Annali Di Igiene: Medicina Preventiva E Di Comunita, 2015, 27, 82-6.	0.7	0
819	Regulation of Molecular Farming Products. Methods in Molecular Biology, 2022, , 313-333.	0.9	7
820	Methods to Produce Monoclonal Antibodies for the Prevention and Treatment of Viral Infections. Russian Journal of Bioorganic Chemistry, 2022, 48, 256-272.	1.0	2
824	COMPUTATIONAL STUDIES OF POTENTIAL EBOLA VP40 INHIBITORS USING BIOACTIVE COMPOUNDS FROM MEDICINAL PLANTS OF MALAYSIA. Jurnal Teknologi (Sciences and Engineering), 2022, 84, 183-190.	0.4	0
825	Antibodies to combat viral infections: development strategies and progress. Nature Reviews Drug Discovery, 2022, 21, 676-696.	46.4	68
826	Intervention of resource allocation strategies on spatial spread of epidemics. Physical Review E, 2022, 105, .	2.1	4
828	Recent Progress in the Discovery and Development of Monoclonal Antibodies against Viral Infections. Biomedicines, 2022, 10, 1861.	3.2	8

#	ARTICLE	IF	CITATIONS
829	Tecovirimat and the Treatment of Monkeypox – Past, Present, and Future Considerations. <i>New England Journal of Medicine</i> , 2022, 387, 579-581.	27.0	106
830	A Review on Edible Vaccines and Biopharmaceutical Products from Plants. <i>Current Pharmaceutical Biotechnology</i> , 2023, 24, 495-509.	1.6	2
831	AAV-monoclonal antibody expression protects mice from Ebola virus without impeding the endogenous antibody response to heterologous challenge. <i>Molecular Therapy - Methods and Clinical Development</i> , 2022, 26, 505-518.	4.1	5
832	Biosensor as quick analytic tool in pandemic!. , 2022, , 169-196.		0
833	Sustainable Manufacturing of Vaccines, Antibodies, and Other Pharmaceuticals. <i>SpringerBriefs in Plant Science</i> , 2022, , 45-59.	0.3	0
834	Humanization and expression of IgG and IgM antibodies in plants as potential diagnostic reagents for Valley Fever. <i>Frontiers in Plant Science</i> , 0, 13, .	3.6	10
835	Energy-efficient production of vaccine protein against porcine edema disease from transgenic lettuce (<i>Lactuca sativa</i> L.). <i>Scientific Reports</i> , 2022, 12, .	3.3	0
836	Anti-SARS-CoV-2 immunoadhesin remains effective against Omicron and other emerging variants of concern. <i>IScience</i> , 2022, 25, 105193.	4.1	7
838	Plant-based expression platforms to produce high-value metabolites and proteins. <i>Frontiers in Plant Science</i> , 0, 13, .	3.6	6
839	Recent Progress on Vaccines Produced in Transgenic Plants. <i>Vaccines</i> , 2022, 10, 1861.	4.4	5
840	A high-throughput single-particle imaging platform for antibody characterization and a novel competition assay for therapeutic antibodies. <i>Scientific Reports</i> , 2023, 13, .	3.3	1
841	The potential of cold-shock promoters for the expression of recombinant proteins in microbes and mammalian cells. <i>Journal of Genetic Engineering and Biotechnology</i> , 2022, 20, 173.	3.3	5
842	Systematic analysis of human antibody response to ebolavirus glycoprotein shows high prevalence of neutralizing public clonotypes. <i>Cell Reports</i> , 2023, 42, 112370.	6.4	2
843	Antibodies against the Ebola virus soluble glycoprotein are associated with long-term vaccine-mediated protection of non-human primates. <i>Cell Reports</i> , 2023, 42, 112402.	6.4	6
844	Structure of the Inmazeb cocktail and resistance to Ebola virus escape. <i>Cell Host and Microbe</i> , 2023, 31, 260-272.e7.	11.0	11
846	Investigating COVID-19 Vaccination Patterns in Europe. <i>Advances in Medical Technologies and Clinical Practice Book Series</i> , 2023, , 219-246.	0.3	0
847	Optimal discrete resource allocation on metapopulation networks for suppressing spatial spread of epidemic. <i>Chaos, Solitons and Fractals</i> , 2023, 169, 113293.	5.1	2
848	Ebanga,ç: The most recent FDA-approved drug for treating Ebola. <i>Frontiers in Pharmacology</i> , 0, 14, .	3.5	4

#	ARTICLE	IF	CITATIONS
849	Plant-based biopharmaceutical engineering. , 2023, 1, 426-439.		24
850	Plant-made vaccines against viral diseases in humans and farm animals. <i>Frontiers in Plant Science</i> , 0, 14, .	3.6	6
852	Human Exposure to Bats, Rodents and Monkeys in Bangladesh. <i>EcoHealth</i> , 0, , .	2.0	0
853	Evaluation of therapeutic PD-1 antibodies by an advanced single-molecule imaging system detecting human PD-1 microclusters. <i>Nature Communications</i> , 2023, 14, .	12.8	1
854	Multidimensional futuristic approaches to address the pandemics beyond COVID-19. <i>Heliyon</i> , 2023, 9, e17148.	3.2	3
855	Plant glycoengineering for designing next-generation vaccines and therapeutic proteins. <i>Biotechnology Advances</i> , 2023, 67, 108197.	11.7	7
856	Ebola virus disease - An update. <i>Indian Journal of Respiratory Care</i> , 2022, 04, 517-520.	0.1	0
857	The New Role of Ethics Committees in Emergency Use of Unproven Interventions Outside Research. , 2023, , 343-369.		0
858	A review of broadly protective monoclonal antibodies to treat Ebola virus disease. <i>Current Opinion in Virology</i> , 2023, 61, 101339.	5.4	3
860	A Monoclonal Antibody Produced in Glycoengineered Plants Potently Neutralizes Monkeypox Virus. <i>Vaccines</i> , 2023, 11, 1179.	4.4	2
861	The Roles of National Ethics Committees in Pandemics. <i>Orientation in Times of Crisis</i> . , 2023, , 281-302.		0
862	Technologies for Making New Vaccines. , 2023, , 1350-1373.e9.		0
863	Ebola Vaccines. , 2023, , 311-329.e6.		0
864	Production and N-glycan engineering of Varilumab in <i>Nicotiana benthamiana</i> . <i>Frontiers in Plant Science</i> , 0, 14, .	3.6	0
865	Protective mechanisms of nonneutralizing antiviral antibodies. <i>PLoS Pathogens</i> , 2023, 19, e1011670.	4.7	2
866	Advances in treatment strategies for COVID-19: Insights from other coronavirus diseases and prospects. <i>Biosafety and Health</i> , 2023, 5, 272-279.	2.7	0
867	Prevention and post-exposure management of occupational exposure to Ebola virus. <i>Lancet Infectious Diseases</i> , The, 2024, 24, e93-e105.	9.1	0
868	Filoviruses: Scientific Gaps and Prototype Pathogen Recommendation. <i>Journal of Infectious Diseases</i> , 2023, 228, S446-S459.	4.0	1

#	ARTICLE	IF	CITATIONS
870	Role of surface glycans in enveloped <scp>RNA</scp> virus infections: A structural perspective. Proteins: Structure, Function and Bioinformatics, 0, , .	2.6	0
871	Plant Molecular Farming: Concept and Strategies. Concepts and Strategies in Plant Sciences, 2023, , 1-34.	0.5	0
872	Plant-Based Antibody Manufacturing. Concepts and Strategies in Plant Sciences, 2023, , 209-233.	0.5	0
873	Functional characterization of AF-04, an afucosylated anti-MARV GP antibody. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2024, 1870, 166964.	3.8	0
874	Biosafety, Risk Analysis, and Regulatory Framework for Molecular Farming in Europe. Concepts and Strategies in Plant Sciences, 2023, , 359-381.	0.5	0
875	Utilizing <scp>nonâ€human</scp> primate models to combat recent <scp>COVID</scp>â€19/<scp>SARSâ€CoV</scp>â€2 and viral infectious disease outbreaks. Journal of Medical Primatology, 2024, 53, .	0.6	0
876	Effect of anti-Ebola virus monoclonal antibodies on endogenous antibody production in survivors of Ebola virus disease in the Democratic Republic of the Congo: an observational cohort study. Lancet Infectious Diseases, The, 2024, 24, 266-274.	9.1	1
877	How enlightened self-interest guided global vaccine sharing benefits all: A modeling study. Journal of Global Health, 0, 13, .	2.7	0
878	Role of miRNA in Ebola diagnosis and therapeutics. , 2024, , 135-163.		0
879	Design of universal Ebola virus vaccine candidates via immunofocusing. Proceedings of the National Academy of Sciences of the United States of America, 2024, 121, .	7.1	0
880	Green horizons: how plant synthetic biology can enable space exploration and drive on Earth sustainability. Current Opinion in Biotechnology, 2024, 86, 103069.	6.6	0
881	Broad antibody and T cell responses to Ebola, Sudan, and Bundibugyo ebolaviruses using mono- and multi-valent adjuvanted glycoprotein vaccines. Antiviral Research, 2024, 225, 105851.	4.1	0
882	Broad Epitope Coverage of Therapeutic Multi-Antibody Combinations Targeting SARS-CoV-2 Boosts In Vivo Protection and Neutralization Potency to Corner an Immune-Evading Virus. Biomedicines, 2024, 12, 642.	3.2	0
883	Filamentous fungus-produced human monoclonal antibody provides protection against SARS-CoV-2 in hamster and non-human primate models. Nature Communications, 2024, 15, .	12.8	0